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SUMMARY 
 
Incidence: new cases per year and stage at diagnosis 
In the most recent three years for which full data are available (2010-2012), on average about 36,000 newly diagnosed 
tumours were registered per year. Of these cases, just over 20,000 involved invasive cancers other than the less serious, 
non-melanoma skin cancers. Over half involved the four most common major malignancies – prostate (3,400 cases per 
year), breast (2,800), colorectal (2,500) and lung cancer (2,300).  
Age-standardised incidence rates of cancer in Ireland in 2012 were estimated to be 10% higher than the European Union 
average for males, and 16% higher than the EU average for females. This included higher Irish rates of colorectal, female 
lung, breast and, especially, prostate cancer, although male lung cancer rates were lower in Ireland. 
Time-trends in cancer incidence since 1994 have varied substantially depending on the cancer type. Overall, age-
standardised incidence rates for invasive cancers have increased by about 1% per year in both males and females 
(throughout 1994-2012). Many individual cancer types have also shown upward trends in annual rates, for example 
lymphomas and prostate, melanoma , kidney, thyroid, cervical, uterine and female lung cancer, although the likely factors 
involved may differ (e.g., screening, lifestyle factors or diagnostic improvements). But some cancers have shown declines 
in incidence rates, notably stomach cancer and male lung cancer.  
For some cancers, there has been a marked shift towards earlier stages at diagnosis – notably for melanoma and for 
breast, prostate, kidney and thyroid cancers – reflecting improvements in early detection.  
Mortality: deaths from cancer 
Cancer remains the second most common cause of death in Ireland, after diseases of the circulatory system. Deaths from 
cancer averaged about 8,800 deaths per year during 2010-2012, representing about 30% of all deaths in that period. Age-
standardised rates of cancer mortality were about 37% higher in men than in women. Lung cancer was by far the single 
most common cause of cancer death during 2010-2012, with approximately 1,800 deaths annually, with deaths from 
colorectal (990), breast (680), prostate (550) and pancreatic cancer (490) the next most common. 
Compared with the EU as a whole, estimated cancer mortality rates in Ireland in 2012 were 14% higher for Irish women 
but were 9% lower for Irish men. For women, lung cancer mortality for Ireland was substantially (34%) higher than the EU 
average.  
Unlike incidence, time-trends in cancer mortality rates have fallen overall throughout 1994-2012, by about 1.5% per year 
in men and about 1.1% per year in women. But, like incidence, the trends have varied by cancer type, although many 
cancer types have shown ongoing reductions in mortality rates since the early 1990s. The exceptions, showing significant 
increases in rates, include melanoma in both sexes and lung and uterine cancer in women. 
Cancer survival 
Trends in cancer mortality reflect changes in both cancer incidence and survival. Survival estimates for most cancer types 
in Ireland have improved over time, although the trend is clearer for some cancers than for others. Some of the more 
striking improvements have been seen for colorectal, breast, kidney, testicular and prostate cancers and for multiple 
myeloma, lymphoma and leukaemia.  However, across ten major cancer types the recently published CONCORD-2 study 
indicated that, in general, Ireland remained approximately mid-way in the ranking of survival estimates among European 
countries. 
Cancer prevalence 
As average survival improves, as incidence (or diagnosis) of many cancers increases, and the population ages, cancer 
prevalence - the number of cancer survivors - in Ireland continues to grow. Of all the patients diagnosed with invasive 
cancer during 1994-2012 (excluding non-melanoma skin cancer), approximately 122,500 were still alive at the end of 
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2012. Of these, almost 94,000 had survived ten years or more since their diagnosis. The growing population of cancer 
survivors has implications for health service provision in the decades ahead. 
Treatment 
The survival improvements seen for some cancers reflect, in part, detection at earlier stages than in earlier years. For the 
majority of cancers, however, improvements in treatment are probably the major contributor to survival improvements. 
Most notably, the use of chemotherapy, either on its own or more frequently in combination with other treatment 
modalities has increased markedly across the majority of relevant cancer types. Radiotherapy use has also increased 
across many cancer types, and the proportion of patients having surgical treatment has increased for some cancers. 
These improvements mean that the overall proportion of cancer patients having tumour-directed treatment (as opposed 
to treatments aimed at symptom relief and palliation) continues to increase. However, the proportion of older patients 
(≥65 years) having no tumour-directed treatment remains high. 
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1. INCIDENCE: 2010-2012 
 
An average of approximately 35,800 cancers was registered per year between 2010 and 2012 inclusive, representing an 
overall age-standardised incidence rate of 747 females cases and 790 males cases per 100,000 per year (Table 1-1). 
Approximately 18% of these were non-invasive tumours (in-situ tumours, tumours of uncertain behaviour and benign 
brain and CNS tumours) and 25% were non-melanoma skin cancers (NMSC, 9,102 cases per year). Looking at figures for 
all invasive cancers only, and excluding NMSC, just over 20,000 cases were registered annually, representing 56% of all 
registered cases and equivalent to an incidence rate of 385 female cases and 493 male cases per 100,000 per year. 
Incidence rates for all invasive cancers combined, excluding NMSC, were 28% higher for men than for women (similar to 
previously published figures), and cumulative lifetime risk remains approximately 1 in 3 for men and 1 in 4 for women. 
Further statistics by individual cancer type are summarised below and, for a longer list of sites, in Appendix I. 
 
Table 1-1. Annual average incidence of the main cancers: 2010-2012 
 CASES RATE**  
(age-standardised) 
per 100,000 
% RISK to age 
75 years 
% of all 
invasive cancers 
site females  males  total females  males  females  males  females  males  total 
C00-C96: All invasive cancers*     13,378      15,788      29,166  543.9 722.1 35.04 44.22 100% 100% 100% 
C00-C43,C45-C96: All invasive 
tumours excluding NMSC* 
     9,312      10,751      20,063  384.5 492.5 26.55 33.63 69.6% 68.1% 68.8% 
D00-D48: All non-invasive tumours      5,110       1,497       6,606  203.0 68.0 14.18 5.26    
C00-D48: All registered tumours     18,488      17,284      35,772  746.9 790.1 44.25 47.15    
mouth & pharynx       129        257        386  5.5 11.9 0.45 1.05 1.0% 1.6% 1.3% 
oesophagus       139        247        386  5.2 11.4 0.39 0.94 1.0% 1.6% 1.3% 
stomach       187        344        530  7.0 15.7 0.48 1.23 1.4% 2.2% 1.8% 
colorectal      1,046       1,439       2,486  41.1 65.6 3.11 4.97 7.8% 9.1% 8.5% 
liver 74 144 217 2.8 6.5 0.21 0.52 0.6% 0.9% 0.7% 
pancreas       228        255        484  8.6 11.7 0.63 0.91 1.7% 1.6% 1.7% 
lung       973       1,300       2,273  39.0 59.3 3.18 4.55 7.3% 8.2% 7.8% 
melanoma skin       496        392        889  20.5 17.8 1.64 1.42 3.7% 2.5% 3.0% 
non-melanoma skin (NMSC)      4,066       5,036       9,102  159.4 229.7 11.55 15.96 30.4% 31.9% 31.2% 
breast      2,816         28       2,844  122.7 1.3 9.64 0.10 21.1% 0.2% 9.8% 
cervix       306         306  13.0  1.01  2.3%  1.0% 
corpus uteri       412         412  17.9  1.61  3.1%  1.4% 
ovary       360         360  15.1  1.23  2.7%  1.2% 
other gynaecological cancers†       103         103         4.2         0.32   0.8%  0.4% 
prostate       3,384       3,384   157.3  13.83  21.4% 11.6% 
testis        176        176   7.3  0.52  1.1% 0.6% 
kidney       191        351        542  7.9 16.1 0.69 1.31 1.4% 2.2% 1.9% 
bladder       129        314        443  4.7 14.3 0.33 1.00 1.0% 2.0% 1.5% 
brain & CNS (malignant)       156        197        353         6.6         8.9        0.53        0.73  1.2% 1.2% 1.2% 
brain & CNS (benign)      117         49        166  4.9 2.2 0.40 0.19    
brain & CNS (uncertain)       34         29         63  1.4 1.3 0.11 0.10    
all lymphoma        388        472        860  16.1 21.4 1.32 1.67 2.9% 3.0% 2.9% 
Hodgkin lymphoma        64         73        137  2.7 3.2 0.21 0.25 0.5% 0.5% 0.5% 
non-Hodgkin lymphoma       324        399        723  13.4 18.2 1.11 1.42 2.4% 2.5% 2.5% 
multiple myeloma       103        141        244  3.9 6.5 0.28 0.48 0.8% 0.9% 0.8% 
all leukaemia       192        297        489  7.9 13.5 0.60 0.98 1.4% 1.9% 1.7% 
other invasive cancers (not listed)‡   958 1,158 2,114     7.2% 7.3% 7.2% 
* invasive cancer included all tumours classified as behaviour 3 in ICD-O-3 classification (including some neoplasms previously classified as 
uncertain behaviour) [1] 
**rates are standardised to the European standard population [16][17] 
† vulva, vagina, uterus (NOS) and placenta 
‡ see Appendix I for more site specific statistics 
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Figure 1-1. Relative frequency of the main invasive cancers diagnosed during 2010-2012 
FEMALES MALES 
  
 
Table 1-2. Ranking of the most commonly diagnosed invasive cancers (excluding NMSC): 2010-2012 
 FEMALES MALES ALL 
 % rank % rank % rank 
All invasive cancers, excluding NMSC 100.0%  100.0%  100.0%  
prostate   31.5% 1 16.9% 1 
breast 30.2% 1   14.2% 2 
colorectal 11.2% 2 13.4% 2 12.4% 3 
lung 10.4% 3 12.1% 3 11.3% 4 
melanoma skin 5.3% 4 3.6% 5 4.4% 5 
lymphoma  4.2% 6 4.4% 4 4.3% 6 
kidney 2.1% 11 3.3% 6 2.7% 7 
stomach 2.0% 12 3.2% 7 2.6% 8 
pancreas 2.5% 9 2.4% 10 2.4% 9 
leukaemia  2.1% 10 2.8% 9 2.4% 10 
bladder 1.4% 16 2.9% 8 2.2% 11 
corpus uteri 4.4% 5   2.1% 12 
mouth & pharynx 1.4% 17 2.4% 11 1.9% 13 
oesophagus 1.5% 15 2.3% 12 1.9% 14 
brain & spinal cord 1.7% 14 1.8% 13 1.8% 15 
ovary 3.9% 7   1.8% 16 
cervix 3.3% 8   1.5% 17 
thyroid 2.0% 13 0.5% 17 1.2% 18 
multiple myeloma 1.1% 18 1.3% 16 1.2% 19 
liver 0.8% 19 1.3% 15 1.1% 20 
testis   1.6% 14 0.9% 21 
Other sites not listed  8.5%  9.2%  8.8%  
 
Of all invasive cancers registered, NMSC was the most common cancer, representing 30% and 32% of all cases in females 
and males respectively (Figure 1-1). If NMSC was excluded, prostate and female breast cancer were the most commonly 
diagnosed cancers overall, and each comprised almost one-third of all cancers in women and men respectively (Table 1-
2). Colorectal and lung cancer were the 2
nd
 and 3
rd
 most common cancers in both sexes respectively, and for these two 
sites combined, their relative contribution to all invasive cancers was still less than that for breast or prostate alone. Little 
change was observed in the relative frequency of individual cancer types from previously reported figures (2009-2011 
average) [2].   
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2. MORTALITY: 2010-2012 
 
Cancer remains the second most common cause of death, after diseases of the circulatory system, and an estimated 
annual average of 8,762 deaths from cancer occurred during the period 2010-2012. This represented approximately 30% 
of all deaths for the period and a mortality rate of approximately 155 female and 212 male deaths per 100,000 persons 
per year (Table 2-1). Almost all cancer deaths were from invasive cancers (97%). All-cancer mortality rates for the period 
2010-2012 were approximately 37% higher in men than in women. The lifetime risk (to age 75 year) of dying from cancer 
during the period 2010-2012 was approximately 1 in 10 for women and 1 in 8 for men. Lung cancer was the single most 
common cause of cancer death during 2010-2012, with approximately 1,780 deaths annually, just over one-fifth of all 
cancer deaths.  
A breakdown of mortality statistics by cancer site is given below and, in more detail, in Appendix II. 
 
Table 2-1. Average annual number of deaths from cancers: 2010-2012 
 DEATHS RATE* 
 (age-standardised) 
per 100,000 
% RISK to age 
75 years 
% of all 
cancer deaths 
site females males total females males females males females males total 
C00-D48: All registered cancer deaths    4,128    4,634    8,762  154.7 211.9 10.49 13.10 100.0% 100.0% 100.0% 
C00-C96: All invasive cancer deaths    3,986    4,480    8,466  150.0 204.9 10.30 12.84 96.6% 96.7% 96.6% 
D00-D48: All non-invasive cancer deaths       142      154      296  4.7 7.1 0.22 0.29 3.4% 3.3% 3.4% 
All cancer invasive deaths, excl. NMSC    3,959    4,428    8,387  149.2 202.4 10.27 12.75 95.9% 95.6% 95.7% 
mouth & pharynx        44       99      143  1.7 4.5 0.13 0.39 1.1% 2.1% 1.6% 
oesophagus       120      230      350  4.2 10.6 0.27 0.81 2.9% 5.0% 4.0% 
stomach       127      199      326  4.5 9.1 0.27 0.64 3.1% 4.3% 3.7% 
colorectal       416      576      992  14.8 26.3 0.95 1.78 10.1% 12.4% 11.3% 
liver 111 153 265 4.0 7.1 0.29 0.52 2.7% 3.3% 3.0% 
pancreas       230      258      488  8.4 11.9 0.55 0.86 5.6% 5.6% 5.6% 
lung       743    1,040    1,783  28.8 47.4 2.20 3.57 18.0% 22.4% 20.4% 
melanoma skin        66       87      153  2.5 4.0 0.18 0.28 1.6% 1.9% 1.7% 
breast       673         9      682  26.4 0.4 2.04 0.03 16.3% 0.2% 7.8% 
cervix        94        94  4.0  0.33  2.3%  1.1% 
corpus uteri        81        81  3.2  0.26  2.0%  0.9% 
ovary       279       279  11.2  0.92  6.8%  3.2% 
other gynaecological cancers  †        56        56      1.3%  0.6% 
prostate      549      549   25.3  1.04  11.9% 6.3% 
testis         5         5   0.2  0.01  0.1% 0.1% 
kidney        57      140      197  2.1 6.4 0.15 0.45 1.4% 3.0% 2.2% 
bladder        78      128      206  2.6 5.8 0.14 0.26 1.9% 2.8% 2.3% 
brain & CNS (malignant)       103      149      251  4.2 6.7 0.35 0.56 2.5% 3.2% 2.9% 
brain & CNS (benign)          8         4       12  0.2 0.2 0.01 0.00 0.2% 0.1% 0.1% 
brain & CNS (uncertain)        10       13       23  0.3 0.6 0.03 0.04 0.2% 0.3% 0.3% 
lymphoma        128      151      280  4.7 6.9 0.32 0.42 3.1% 3.3% 3.2% 
Hodgkin lymphoma        11       10       21  0.4 0.4 0.02 0.03 0.3% 0.2% 0.2% 
non-Hodgkin lymphoma       117      141      258  4.3 6.4 0.30 0.38 2.8% 3.1% 2.9% 
multiple myeloma        76       79      155  2.6 3.6 0.16 0.24 1.8% 1.7% 1.8% 
leukaemia        86      133      219  3.0 6.0 0.17 0.38 2.1% 2.9% 2.5% 
other cancer deaths ‡       652      785    1,438      15.8% 16.9% 16.4% 
*rates are standardised to the European standard population 
† vulva, vagina, uterus (NOS), placenta  
‡ see Appendix II for site specific data 
 
  
Cancer in Ireland 1994-2012                                                Page 7 
 
 
Figure 2-1. Relative frequency of the main invasive cancer deaths : 2010-2012 
 
FEMALES MALES 
  
 
 
Table 2-2. Ranking of the most common cancer deaths: 2010-2012   
 FEMALES MALES ALL 
 % rank % rank % rank 
lung 18.0% 1 22.4% 1 20.4% 1 
colorectal 10.1% 3 12.4% 2 11.3% 2 
breast 16.3% 2   7.8% 3 
prostate   11.9% 3 6.3% 4 
pancreas 5.6% 5 5.6% 4 5.6% 5 
oesophagus 2.9% 8 5.0% 5 4.0% 6 
stomach 3.1% 6 4.3% 6 3.7% 7 
ovary 6.8% 4   3.2% 8 
lymphoma 3.1% 7 3.3% 7 3.2% 9 
liver 2.7% 9 3.3% 8 3.0% 10 
brain & spinal cord 2.5% 10 3.2% 9 2.9% 11 
leukaemia 2.1% 12 2.9% 11 2.5% 12 
bladder 1.9% 14 2.8% 12 2.3% 13 
kidney 1.4% 17 3.0% 10 2.2% 14 
multiple myeloma 1.8% 15 1.7% 15 1.8% 15 
melanoma skin 1.6% 16 1.9% 14 1.7% 16 
mouth & pharynx 1.1% 18 2.1% 13 1.6% 17 
cervix 2.3% 11   1.1% 18 
corpus uteri 2.0% 13   0.9% 19 
other gynaecological 1.1% 19   0.6% 20 
other cancer deaths 13.6%  14.2%  13.9%  
 
Lung cancer was the leading cause of cancer death in both sexes, comprising 18% of cancer deaths in women and 22% of 
cancer deaths in men during the period 2010-2012 (Figure 2-1). Deaths from lung, colorectal, breast and prostate cancers 
combined made up almost half of all deaths from cancer during this period. Deaths from cancers of the ovary and 
pancreas in females, and from cancers of the pancreas, oesophagus and stomach in males, together made up 12% and 
15% respectively of all cancer deaths. These sites respectively ranked as the 4
th
 and 5
th
 most common causes of cancer 
death in women and the 4
th
 to 6
th
 most common in men (Table 2-2). Comparison with the lower cancer incidence ranking 
for pancreas and oesophagus in particular (Table 1-2) provides a clear indicator of the high mortality:incidence ratio for 
these cancers, reflecting their poor prognosis.  
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3. INCIDENCE AND MORTALITY: IRELAND AND EUROPE  
The European Cancer Observatory (ECO) has been developed in collaboration between IARC and 130 ENCR member 
registries [3][4]. ECO provides a comprehensive window on cancer incidence, mortality, prevalence and survival for 
Europe as a whole and for individual countries and registries. Estimates of cancer incidence and mortality in Ireland are 
presented for 2012 (Figures 3-1, 3-2). The average pooled estimates for the 27 members of the EU (in 2012) are 
presented for comparison. 
 
Figure 3-1. Comparison of estimated incidence and mortality rates in Ireland with EU(27) average rates in 2012: 
all cancer sites, invasive tumours, excluding NMSC: European Cancer Observatory
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The age-standardised incidence rate in Irish males was 500/100,000, which was substantially higher than the EU average 
(453/100,000), partly due to increased diagnosis of prostate cancer in Ireland (Figure 3-2). Similarly, the incidence rate in 
females was 382/100,000, considerably higher than the EU average (330/100,000), mostly reflecting higher incidence of 
lung, breast and colorectal cancer among Irish females (Figure 3-2).  
It cannot be excluded that some of this international variation might reflect differences in completeness of cancer 
registration. Almost half of the population of Europe falls outside the coverage of cancer registration and some countries 
may not have recorded all incident cancer cases that occurred within their borders, or incidence may have been 
estimated from mortality statistics. Some countries have regional registries that do not cover the whole population of the 
country (e.g. Spain, Italy, Poland, France and Germany) [5]. Ireland has a national cancer registry which covers the whole 
population (since 1994) and completeness of registration is estimated as 98% [6].  
The mortality rate estimate from cancer in males was 193/100,000, which was slightly lower than the EU27 average 
(212/100,000), partly due to lower than average mortality rates from lung cancer (Figure 3-2). Conversely, the mortality 
rate in females was higher than the EU27 average: 146 vs. 128/100,000 respectively. This was largely due to the higher 
death rates for lung, breast and ovarian cancer in Irish females relative to the European average (Figure 3-2).   
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Figure 3-2. Comparison of estimated incidence and mortality rates in Ireland with EU(27) average rates in 2012: 
invasive tumours, excluding NMSC: European Cancer Observatory [3][4] 
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4. TRENDS IN INCIDENCE AND MORTALITY IN IRELAND: 1994-2012 
 
 
Figure 4-1.c (rightmost) shows trends in incidence and mortality for invasive cancer during 
the period 1994-2012. During 2010-2012 the incidence rate averaged 385/100,000 and 
493/100,000 for females and males respectively. The annual rate of cancer incidence 
increased significantly and quite steadily at 1.2% in males and 1.0% in females over the 
period 1994-2012, probably largely due to improved detection (including screening for 
some cancers).  
During 2010-2012 the average mortality rate was 212/100,000 and 155/100,000 for males 
and females respectively. The annual rate of cancer mortality decreased significantly and 
steadily at 1.5% for males and 1.1% for females during 1994-2012 largely due to 
improvements in treatment and earlier diagnosis.  
Figure 4-1.b (middle) shows the substantially higher rate of incidence of non-invasive 
cancers in females compared to males, which was due to in situ cervix and breast tumours 
which together comprise over 50% all non-invasive tumours regardless of sex (2010-2012: 
Appendix I). The recent increase in the rate of non-invasive cancers in females at 6% 
annually since 2002 largely reflected the implementation of the national breast and (more 
recently) cervical screening programmes. The increased rate in males (by 8% annually) since 
2004 was due in part to increases in cases presenting with in situ skin cancers. 
Figure 4-1. a-c: trends in incidence and mortality: 1994-2012 
 a. C00-C96: All invasive cancers b. D00-D48: All non-invasive cancers c. C00-C43, C45-C96: all invasive cancers, excluding NMSC 
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  sex from to APC 95%CI trend 
incidence female 1994 1999 0.1 -1.1 1.4 ↔ 
incidence female 1999 2012 1.5 1.2 1.7 ↑ 
incidence male 1994 1998 -0.5 -2.3 1.4 ↔ 
incidence male 1998 2012 1.5 1.3 1.8 ↑ 
mortality female 1994 2012 -1.1 -1.3 -0.9 ↓ 
mortality male 1994 2012 -1.5 -1.7 -1.3 ↓ 
 
 sex from to APC 95%CI trend 
incidence female 1994 2002 2.2 -1.1 5.7 ↔ 
incidence female 2002 2012 6.4 4.6 8.2 ↑ 
incidence male 1994 2004 5.3 3.8 6.8 ↑ 
incidence male 2004 2012 8.4 7.1 9.8 ↑ 
mortality female 1994 2012 9.0 6.3 11.7 ↑ 
mortality male 1994 2012 10.0 6.8 13.4 ↑ 
 
 sex from to APC 95%CI trend 
incidence female 1994 2012 1.0 0.9 1.2 ↑ 
incidence male 1994 2012 1.2 1.0 1.4 ↑ 
mortality female 1994 2012 -1.1 -1.3 -0.9 ↓ 
mortality male 1994 2012 -1.5 -1.7 -1.4 ↓ 
 
APC: annual percentage change; trend: ↑=significant increase, ↓=significant decrease, ↔=no change, at the 95% level; calculated using Joinpoint regression with 5 years set as minimum constraint for allowance of inflexion point(s) 
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Figure 4-1. d-f: trends in incidence and mortality: 1994-2012 
 d. C01-C14: mouth & pharynx e. C15: oesophagus f. C16: stomach 
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  sex from to APC 95%CI trend 
incidence female 1994 2012 2.4 1.3 3.6 ↑ 
incidence male 1994 2001 -4.2 -6.2 -2.1 ↓ 
incidence male 2001 2012 2.5 1.5 3.5 ↑ 
mortality female 1994 2012 -1.3 -2.5 0.0 ↔ 
mortality male 1994 2012 -2.0 -2.8 -1.1 ↓ 
 
 sex from to APC 95%CI trend 
incidence female 1994 2012 -0.9 -1.5 -0.2 ↓ 
incidence male 1994 2012 0.0 -0.7 0.7 ↔ 
mortality female 1994 2012 -1.9 -2.6 -1.2 ↓ 
mortality male 1994 2012 -0.8 -1.4 -0.2 ↓ 
 
 sex from to APC 95%CI trend 
incidence female 1994 2012 -1.5 -2.1 -1.0 ↓ 
incidence male 1994 2002 -3.0 -4.5 -1.4 ↓ 
incidence male 2002 2012 -0.6 -1.7 0.5 ↔ 
mortality female 1994 2012 -3.4 -4.0 -2.8 ↓ 
mortality male 1994 2012 -3.3 -3.8 -2.7 ↓ 
 
 
Tobacco and alcohol are established risk factors for the cancers detailed in Figure 4-1.d-f 
above [7]. h. pylori infection is also an established risk factor for stomach cancer [8].  
The incidence rate of mouth/pharyngeal cancer has increased by 2.5% annually for males 
since 2001 and 2.4% annually for women since 1994. There has been no significant change 
in the mortality rate in females since 1994, whereas mortality has decreased in males by 2% 
annually since 1994 (Figure 4-1.d).  
 
 
There was no significant change in the annual incidence rate for oesophageal cancer in 
males, but the rate in females decreased by almost 1% annually during 1994-2012. The 
mortality rate decreased by 2% annually in females, and by almost 1% annually in males 
during the same period (Figure 4-1.e). 
The incidence rate of stomach cancer in males decreased significantly by 3% annually up to 
2002 – thereafter, the annual rate reduction stalled somewhat throughout 2002-2012 (<1% 
annual decrease) (Figure 4-1.f). In females, the incidence rate decreased steadily by 1.5% 
annually during 1994-2012. The mortality rate decreased significantly by >3% annually in 
both males and females.  
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Figure 4-1. g-i: trends in incidence and mortality: 1994-2012 
 g. C18-C21: colorectal h. C25: pancreas i. C34: lung 
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  sex from to APC 95%CI trend 
incidence female 1994 2012 0.1 -0.2 0.4 ↔ 
incidence male 1994 2012 0.2 -0.1 0.4 ↔ 
mortality female 1994 2012 -2.0 -2.5 -1.5 ↓ 
mortality male 1994 2012 -1.6 -2.1 -1.2 ↓ 
 
 sex from to APC 95%CI trend 
incidence female 1994 2012 0.5 -0.2 1.2 ↔ 
incidence male 1994 2012 0.6 -0.2 1.4 ↔ 
mortality female 1994 2012 0.3 -0.2 0.8 ↔ 
mortality male 1994 2005 -1.3 -2.6 0.0 ↔ 
mortality male 2005 2012 2.4 0.2 4.7 ↑ 
 
 sex from to APC 95%CI trend 
incidence female 1994 2012 2.2 2.0 2.5 ↑ 
incidence male 1994 2012 -0.7 -1.0 -0.5 ↓ 
mortality female 1994 2012 0.5 0.2 0.9 ↑ 
mortality male 1994 2012 -1.8 -2.1 -1.5 ↓ 
 
 
The incidence rate of colorectal cancer in males and females did not change significantly 
during 1994-2012 (Figure 4-1.g). The mortality rate decreased significantly by 2% annually in 
females and 1.6% in males over the same period. The reduction in mortality was due in part 
to advances in treatment strategy over the last two decades.  
Pancreatic cancer has a very poor prognosis, with fewer than 1 in 10 patients surviving 
beyond five years. Incidence has shown a slight but non-significant increase, by <1% 
annually, in both males and females. The mortality rate increased at 2.4% annually in males 
during 2005-2012, but this followed an apparent decrease during 1994-2005 so the true 
trend may be unclear. Mortality remained fairly static in females (possibly a slow increase) 
during 1994-2012 (Figure 4-1.h).  
 
 
 
Lung cancer also has a poor prognosis, with only 1 in 7 surviving beyond five years after 
diagnosis. The incidence rate of lung cancer declined steadily in males at almost 1% 
annually during 1994-2012, whereas in females it increased significantly at over 2% annually 
over the same period (Figure 4-1.i). The same trends in incidence are apparent in other 
northern and western European countries [5]. The lung cancer mortality rate in Ireland 
decreased significantly, by almost 2% annually, in males but increased by 0.5% annually in 
females during 1994-2012. These trends reflect smoking prevalence from decades earlier, 
but the contrast between males and females is striking.  
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Figure 4-1. j-l: trends in incidence and mortality: 1994-2012 
 j. C43: melanoma skin k. C44: non-melanoma skin (NMSC) l. C50: breast (female) 
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  sex from to APC 95%CI trend 
incidence female 1994 2012 2.7 2.0 3.4 ↑ 
incidence male 1994 2012 4.8 4.1 5.6 ↑ 
mortality female 1994 2012 2.2 0.6 3.7 ↑ 
mortality male 1994 2012 5.6 4.0 7.3 ↑ 
 
 sex from to APC 95%CI trend 
incidence female 1994 2001 -0.5 -1.9 0.9 ↔ 
incidence female 2001 2012 2.8 2.2 3.4 ↑ 
incidence male 1994 2001 -1.9 -3.0 -0.8 ↓ 
incidence male 2001 2012 3.2 2.7 3.7 ↑ 
mortality female 1994 2012 4.0 1.5 6.5 ↑ 
mortality male 1994 2012 3.6 2.0 5.1 ↑ 
 
invasive from to APC 95%CI trend 
incidence 1994 2012 1.7 1.2 2.1 ↑ 
mortality 1994 2012 -1.9 -2.3 -1.5 ↓ 
 
in-situ from to APC 95%CI trend 
incidence 1994 2012 9.2 7.7 10.7 ↑ 
 
 
For melanoma skin cancer, the rate of incidence in females increased at almost 3% annually 
during the period 1994-2012, and in males by almost 5% over the same period. The 
mortality rate increased by 2.2% annually in females, and almost 6% in males (Figure 4-1.j).  
For non-melanoma skin cancer (NMSC), the incidence rate has increased by about 3% 
annually since 2001 in both males and females. Only a very small proportion of all cancer 
deaths are due to NMSC (<1% during 2010-2012), nevertheless, the annual mortality rate 
increased at 3-4% annually for both sexes during 1994-2012 (Figure 4-1.k). 
 
The prognosis for breast cancer has improved since the 1990s due to earlier diagnosis and 
advances in treatment, with >80% net survival at five years in recent years (Figure 9-1). The 
incidence rate increased by 1.7% annually during the period 1994-2012 (Figure 4-1.l). In 
large part, the incidence trend for malignant breast cancer reflects the advent of the 
national breast screening program which was implemented in the eastern half of the 
country from 2000 and was extended to the rest of the country by 2007. The mortality rate 
decreased significantly at almost 2% annually during 1994-2012. The effect of the screening 
program is also evident in the highly significant 9% annual increase the incidence rate of in 
situ breast tumours (Figure 4-1.l).  
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Figure 4-1. m-o: trends in incidence and mortality: 1994-2012 
 m. C53: cervix n. C54: corpus uteri o. C56: ovary 
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 invasive from to APC 95%CI trend 
incidence 1994 2012 1.8 0.7 2.9 ↑ 
mortality 1994 2012 -0.4 -1.3 0.4 ↔ 
 
in-situ from to APC 95%CI trend 
incidence 1994 2012 5.4 4.1 6.7 ↑ 
 
 from to APC 95%CI trend 
incidence 1994 2012 2.5 1.8 3.1 ↑ 
mortality 1994 2012 2.3 1.2 3.4 ↑ 
 
 from to APC 95%CI trend 
incidence 1994 2012 -0.7 -1.3 -0.1 ↓ 
mortality 1994 2012 -0.6 -1.3 0.0 ↔ 
 
 
Screening activity has had an impact on cervical cancer incidence. The incidence rate for 
invasive tumours increased by almost 2% annually during 1994-2012 (Figure 4-1.m). 
Mortality rates have declined non-significantly by 0.4% annually. The number of in situ 
cervical cancers diagnosed per year increased significantly at 5.4% annually during the same 
period, mainly due to screening.  
Incidence of uterine cancer (corpus uteri) increased significantly at 2.5% annually and 
mortality at 2.3% annually during 1994-2012 (Figure 4-1.n).  
 
 
 
 
The incidence rate of ovarian cancer decreased significantly by 0.7% annually during 1994-
2012, while the mortality rate declined (albeit non-significantly) by about 0.6% per annum 
during the same period (Figure 4-1.o). Most ovarian cancer patients are diagnosed at late 
stage and average survival is poor – five-year relative survival in Ireland for the population 
diagnosed in 2000-2007 was 30% compared to nearly 38% for the European average [9]. For 
the more recent diagnosis period in Ireland, 2006-2011, five-year net survival was 32% 
(Figure 9-2).  
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Figure 4-1. p-r: trends in incidence and mortality: 1994-2012 
 p. C61: prostate q. C64: kidney r. C67: bladder 
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  from to APC 95%CI trend 
incidence 1994 2004 7.6 6.3 9.0 ↑ 
incidence 2004 2012 1.6 0.4 2.9 ↑ 
mortality 1994 2001 -0.2 -1.8 1.4 ↔ 
mortality 2001 2012 -2.6 -3.3 -1.8 ↓ 
 
 sex from to APC 95%CI trend 
incidence female 1994 2012 3.2 2.5 3.9 ↑ 
incidence male 1994 2012 3.0 2.4 3.6 ↑ 
mortality female 1994 2008 1.2 -0.5 2.9 ↔ 
mortality female 2008 2012 -7.2 -16.5 3.1 ↔ 
mortality male 1994 2012 1.1 0.0 2.1 ↔ 
 
 sex from to APC 95%CI trend 
incidence female 1994 2012 -2.3 -3.3 -1.2 ↓ 
incidence male 1994 2012 -2.8 -3.2 -2.4 ↓ 
mortality female 1994 1999 -6.6 -14.1 1.5 ↔ 
mortality female 1999 2012 2.0 0.1 3.9 ↑ 
mortality male 1994 2012 -1.2 -2.0 -0.5 ↓ 
 
 
For prostate cancer, the incidence rate increased dramatically, by nearly 8% annually, 
between 1994 and 2004, and then by 1.6% annually from 2004 to 2012 (Figure 4-1.p). The 
increased incidence over the last two decades probably largely reflects large-scale PSA 
testing of asymptomatic men. The number of PSA tests carried out increased five-fold 
between 1995 and 2004 [10]. The prostate cancer mortality rate decreased significantly at 
2.6% annually during 2001-2012.  
The incidence rate of kidney cancer has increased by about 3% annually for both females 
and males since 1994 (Figure 4-1.q). Mortality rates did not change significantly during 
1994-2012 in either sex.  
 
The incidence rate of invasive bladder cancers decreased by 2.3% annually in females, and 
by 2.8% annually in males over the period 1994-2012. However, the magnitude of the 
downward trend may be exaggerated somewhat by possible changes in coding (a higher 
proportion may have been coded as non-invasive in more recent years). The mortality rate 
increased at 2% per annum in females during 1999-2012, and decreased in male at 1.2% 
annually during 1994-2012 (Figure 4-1.r). 
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Figure 4-1. s-u: trends in incidence and mortality: 1994-2012 
 s. C71-C72: brain & CNS t. D32-D33: benign brain & CNS u. C73: thyroid 
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  sex from to APC 95%CI trend 
incidence female 1994 2012 0.2 -0.6 1.1 ↔ 
incidence male 1994 2012 0.0 -0.5 0.5 ↔ 
mortality female 1994 2012 -1.1 -2.1 -0.2 ↓ 
mortality male 1994 2012 -0.6 -1.5 0.3 ↔ 
 
 sex from to APC 95%CI trend 
incidence female 1994 2012 1.2 0.2 2.2 ↑ 
incidence male 1994 2012 0.0 -1.5 1.5 ↔ 
mortality female 1994 2000 33.2 8.9 62.8 ↑ 
mortality female 2000 2012 -7.0 -11.5 -2.3 ↓ 
mortality male 1994 1998 100.3 -22.8 419.8 ↔ 
mortality male 1998 2012 -4.2 -11.4 3.6 ↔ 
 
 sex from to APC 95%CI trend 
incidence female 1994 2002 3.0 -3.6 10.0 ↔ 
incidence female 2002 2012 11.1 7.8 14.5 ↑ 
incidence male 1994 1999 -5.1 -17.5 9.2 ↔ 
incidence male 1999 2012 7.4 4.8 10.2 ↑ 
mortality female 1994 2012 -3.7 -5.3 -2.1 ↓ 
mortality male 1994 2012 0.1 -1.7 2.0 ↔ 
 
 
There was no change for males or females in the incidence rate of invasive brain/CNS 
tumours during the period 1994-2012. The mortality rate for invasive tumours declined 
significantly in females by 1.1% annually, but not in males (-0.6% annually) (Figure 4-1.s).  
For benign brain & CNS tumours, there was a 1.2% annual increase in the incidence rate in 
females during 1994-2012, and no change in the male incidence rate over the same period. 
Mortality rates for benign brain & CNS tumours are much lower than for invasive tumours, 
with only 12 deaths annually during 2010-2012 (Appendix II). The mortality rate has 
decreased by 7% annually (since 2000) and 4% annually (since 1998) for females and males 
respectively, but based on very small numbers (Figure 4-1.t).  
 
 
 
Thyroid cancers are infrequent, and between 2010 and 2012 they comprised 2% of all 
female cancers and just 0.5% of male cancers. The female incidence rate increased 
significantly, by 11% annually during 2002-2012, while the male rate increased by 7.4% 
annually during 1999-2012 (Figure 4-1. u). These trends are likely to reflect an increase in 
‘incidental’ detection of thyroid cancers during investigations for other conditions. The 
mortality rate has decreased in females by nearly 4% annually since 1994 but has remained 
static in males (Figure 4-1.u). Similar increases in thyroid cancer incidence have been seen 
in other countries [11][12].  
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Figure 4-1. v-x: trends in incidence and mortality: 1994-2012 
 v. C81-C85: lymphoma (all) w. C81: Hodgkin lymphoma x. C82-C85: non-Hodgkin lymphoma 
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  sex from to APC 95%CI trend 
incidence female 1994 2012 1.6 1.1 2.2 ↑ 
incidence male 1994 2012 1.8 1.3 2.2 ↑ 
mortality female 1994 2012 -1.2 -2.4 0.0 ↔ 
mortality male 1994 2012 -1.1 -2.0 -0.3 ↓ 
 
 sex from to APC 95%CI trend 
incidence female 1994 2012 2.1 0.6 3.6 ↑ 
incidence male 1994 2012 1.9 1.0 2.8 ↑ 
mortality female 1994 2012 -1.6 -4.2 1.2 ↔ 
mortality male 1994 2012 -5.4 -7.5 -3.2 ↓ 
 
 sex from to APC 95%CI trend 
incidence female 1994 2012 1.6 1.0 2.2 ↑ 
incidence male 1994 2012 1.8 1.3 2.3 ↑ 
mortality female 1994 1999 4.8 -3.9 14.3 ↔ 
mortality female 1999 2012 -2.5 -4.3 -0.6 ↓ 
mortality male 1994 2012 -0.7 -1.6 0.2 ↔ 
 
 
Lymphomas are a heterogeneous group of cancers of the haematopoietic system, classified 
as two distinct groups based on histological appearance. They comprise just under half of all 
haematopoietic cancers (along with leukaemia, multiple myeloma and similar 
malignancies). The incidence rate for lymphomas as a whole increased steadily by 1.6% 
annually in females, and by 1.8% in males during the period 1994-2012. The mortality rate 
decreased significantly in males at 1.1% annually, but not significantly in females (-1.2%) 
(Figure 4-1.v).  
The incidence rate for Hodgkin lymphoma increased steadily by 2.1% annually in females, 
and by 1.9% annually in males during 1994-2012. The mortality rate decreased significantly 
at 5.4% annually in males, and not significantly (-1.6%) in females over the same period 
(Figure 4-1.w).  
 
 
Non-Hodgkin lymphoma cases are diagnosed at approximately five times the frequency of 
Hodgkin lymphoma The incidence rate for non-Hodgkin lymphoma increased significantly 
and steadily by 1.6% annually in females and 1.8% in males during the period 1994-2012. 
The mortality rate decreased significantly by 2.5% annually in females during 1999-2012, 
but not in males (-0.7% annually during 1994-2012) (Figure 4-1.x). 
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Figure 4-1. y-z: trends in incidence and mortality: 1994-2012 
  y. C90: multiple myeloma z. C91-C95: leukaemia (total) 
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  sex from to APC 95%CI trend 
incidence female 1994 2012 0.0 -1.2 1.2 ↔ 
incidence male 1994 2012 0.0 -0.7 0.8 ↔ 
mortality female 1994 2012 -2.0 -3.2 -0.9 ↓ 
mortality male 1994 2012 -2.0 -2.8 -1.2 ↓ 
 
 sex from to APC 95%CI trend 
incidence female 1994 2012 0.0 -0.9 0.8 ↔ 
incidence male 1994 2004 3.2 2.1 4.4 ↑ 
incidence male 2004 2012 -3.2 -4.6 -1.9 ↓ 
mortality female 1994 2001 3.5 -0.6 7.7 ↔ 
mortality female 2001 2012 -4.9 -6.7 -2.9 ↓ 
mortality male 1994 2004 2.7 0.7 4.7 ↑ 
mortality male 2004 2012 -6.4 -8.8 -3.9 ↓ 
 
Multiple myeloma is a cancer of plasma cells (immunoglobulin-producing B-lymphocytes), 
where abnormal plasma cells accumulate in the bone marrow and interfere with 
haematopoiesis. The incidence rate did not change during the period 1994-2012, but the 
mortality rate decreased by 2% annually in both males and females over the same period 
(Figure 4-1.y).  
 
 
 
Leukaemia comprised about one quarter of all cancers of the haematopoietic system during 
2010-2012. The incidence rate in males decreased significantly by 3.2% annually during 
2004-2012, following an earlier period of increase; there was no change in incidence among 
females over the same period. The mortality rate decreased at 4.9% annually in females 
during 2001-2012, and at 6.4% in males during 2004-2012 (Figure 4-1.z). 
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5. AGE PROFILE OF PATIENTS AT DIAGNOSIS AND DEATH 
 
Figure 5-1. Age profile of patients at diagnosis: 2010-2012 
 
numbers in parentheses- median age at diagnosis 
 
Approximately 15% of all patients were under 50 years of age when diagnosed with invasive cancer, excluding NMSC 
(Figure 5-1). The proportions of all patients aged between 50 and 64, between 65 and 74, and over 75 were fairly similar 
and the median age overall was 67 years. The age profile of individual cancer types varied considerably however. Over 
two-thirds of patients with cancers of the stomach, pancreas, bladder, oesophagus, colon, lung and prostate as well as 
multiple myeloma were diagnosed when aged 65 or over. In contrast patients diagnosed with in situ cervical cancer, 
invasive testicular cancer and Hodgkin lymphoma were very young by comparison, with median ages of 31, 32 and 35 
respectively.  
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Figure 5-2. Age profile of cancer patients at death: 2010-2011 
 
numbers in parentheses- median age at death 
 
The median age at death from cancer during the period 2010-2011 was 73 years, and 46% deaths occurred at ages ≥75 
years (Figure 5-2). Median age at death for patients dying from non-melanoma skin cancer (NMSC) was 81 years, 
representing the oldest group overall, although they comprised just 1% of all cancer deaths (about 80 deaths per annum 
2010-2012). Prostate and bladder cancer patients had the next highest median ages at death overall (80 and 79 years 
respectively) and over two-thirds of these patients were aged 75 or older at death. For the most part, those cancers that 
were diagnosed at older ages tended to have a similar age profile at death, and patients with stomach, pancreas and lung 
cancer had very similar median ages at diagnosis and death. The greatest differences between median ages at diagnosis 
and death were observed for patients with testicular cancer and Hodgkin lymphoma. Over 96% of all testicular cancer 
patients were under 50 when diagnosed; only 67% of patients were in this age group at death, when the median age was 
44 years. Similarly for Hodgkin lymphoma patients, median age was 35 years at diagnosis but 74 years at death, and 48% 
of patients were aged at least 75 when they died. 
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6. STAGE AT DIAGNOSIS 
 
Stage is important for assessment of prognosis and selection of an appropriate treatment regimen. The distribution of 
TNM 5
th
-edition stage at diagnosis over two diagnostic periods (1995-2003 and 2004-2012) is presented in Figure 6-1. For 
some cancers, there has been a marked shift towards earlier stage at diagnosis – notably for melanoma and for breast, 
prostate and thyroid cancers – reflecting a trend towards early detection. Changes in stage distribution are less clear for 
many other cancers, but in general the proportion of cases lacking adequate stage information has fallen over time, which 
suggests improvements in diagnostic methods with implications for more targeted treatment (Figure 6-1).  
For some cancers, changes in staging criteria over time may also have contributed (artefactually) to apparent trends. In 
particular, a high proportion of cases staged in the earlier period were staged according to 4
th
-edition TNM criteria, and 
translation to 5
th
-edition TNM (as presented in Figure 6-1) was not always possible. This caveat applies particularly to 
cancers of the mouth and pharynx, stomach, pancreas, kidney, and bladder, of those presented here. 
For invasive cancers as a whole (excluding NMSC), the proportion of unstaged cancers decreased from 36% to 25% 
between the periods 1995-2003 and 2004-2012. The greatest proportion of unstaged tumours was for oesophageal 
cancer, 49% and 39% in the earlier and later period, respectively. Breast cancer had the smallest proportion of unstaged 
tumours, and the proportion decreased from 8% to 6%.  
During the earlier period a large proportion of prostate tumours were unstaged (39%); in the later period this proportion 
fell to 13%, coinciding with a large increase in the proportion of stage II tumours (from 36% to 66%). This was probably 
driven by an increase in opportunistic screening and diagnostic investigation resulting from increased use of PSA testing.  
The proportion of unstaged colorectal tumours changed little from the earlier to the later period (10-12% for colon, and 
14% for rectum). However, the relative proportion of stage III/IV tumours increased for colon cancer from 45% to 49% 
and for rectal cancer from 41% to 50%, suggesting more complete investigation of cases that might previously have been 
assigned a lower stage. 
The proportion of unstaged lung cancer cases decreased from 28% to 15%, concomitant with an increase in the 
proportion of stage III/IV tumours (51% to 63% for the earlier and later period respectively) (Figure 6-1).  
There was little change in the stage proportions for cervical cancer and cancer of the corpus uteri. Ovarian cancer was the 
only cancer where the unstaged proportion actually increased from the earlier to the later period (14% to 17%) (Figure 6-
1).  
Among less common cancers, kidney cancer showed the biggest relative reduction in unstaged cancers, from 36% to 8% 
between the two periods examined. However, this reflects (at least in part) the difficulty of converting 4
th
-edition TNM 
stage to the 5
th
-edition equivalent for this cancer. The proportion of stage I thyroid cancer increased substantially from 
37% to 52% from the earlier to the later period, which is notable in the light of the increased diagnosis of this infrequent 
cancer in recent years (Figure 4-1. u) (Figure 6-1).  
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Figure 6-1.  Percentage distribution of TNM 5
th
-edition stage of disease at diagnosis by cancer site: 1995-2003, 2004-2012 
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7. PREVALENCE: 1994-2012 
 
Follow-up of all registered patients (through matching of registrations to death certificates) is currently complete to the 
end of 2012. From the beginning of 1994 (when national cancer registration began in Ireland) to the end of 2012, a total 
of 135,043 females and 147,788 males were diagnosed with invasive cancer. Some patients had more than one cancer 
diagnosis and, for the purposes of Table 7-1, patients were counted once only, choosing either their first invasive cancer 
or the cancer with the higher fatality rank in cases with synchronous cancers of different types [13]. Total prevalence for 
this 19 year period shows that 122,452 of these patients were still alive at end 2012, representing 46% of all female and 
40% of all male cancer patients, and nearly 3% of the whole Irish population (Table 7-1).  
 
Table 7-1. Prevalence of invasive cancer (excluding NMSC) in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % 
alive† 
alive % alive alive % alive alive % alive alive % alive 
female 62,739 46 45,731 58 28,690 68 18,944 73 7,218 83 
male 59,713 40 47,841 54 30,709 65 20,863 72 7,990 83 
‡<65  53,983 57 43,436 70 29,179 79 19,952 84 7,621 92 
‡65+ 68,469 36 50,136 48 30,220 57 19,855 64 7,587 75 
Total 122,452 43 93,572 56 59,399 66 39,807 72 15,208 83 
‡ refers to age category of patient at end of 2012 
†Figures for ‘% alive’ should not be interpreted or used as survival estimates because length of follow-up is not taken into account 
 
As prevalence takes all patients into account, the majority of those still alive are patients diagnosed in recent years. 
However prevalence can be a good indicator of cancer burden, particularly when shorter time periods are examined. for 
example one-year prevalence provides an estimate of the number of patients currently undergoing treatment or just 
recently completing their treatment (c.15,200), three-year prevalence gives an indication of the number of these patients 
together with those who may have completed treatment but are still under clinical surveillance or follow-up (c.39,800).  
Prevalence for various periods for lung, breast, prostate and colorectal cancers as well as other common cancers is 
presented in Tables 7-2 to 7-23. Note that, for individual cancer types, each patient is counted only once, based on their 
earliest diagnosis with that cancer type. 
A total of 1,118 patients diagnosed with lung cancer during 2012 were still alive at the end of that year (one-year 
prevalence) (Table 7-2). This represents 56% of all patients diagnosed who are likely to be still undergoing or just 
completed treatment. Three-year prevalence for lung cancer indicated that 2,032 patients (34% of all those diagnosed) 
were likely to be still undergoing treatment or follow-up clinical surveillance for lung cancer at the end of 2010. Lung 
cancer has very high mortality; of all cases diagnosed in the 19 year period 1994-2012 (over 33,000) only 11% remain alive 
at the close of 2012.  
A total of 14,862 colorectal cancer patients, 27,271 breast cancer patients and 25,358 prostate cancer patients diagnosed 
since 1994 were still alive at the end of 2012, representing 40%, 67% and 63% of all patients diagnosed during the 19-year 
period respectively (Tables 7-3, 7-4, 7-5). These cancers all have a better prognosis than lung cancer, and focusing on 
those patients who are likely to be still under active treatment or clinical follow-up (three-year prevalence) gives totals for 
colorectal cancer of 4,896 (74% of all patients diagnosed), for breast cancer 7,602 (93% of all patients diagnosed) and 
9,004 for prostate cancer (93% of all patients diagnosed). 
The majority of patients in the prevalent population in 2012 were those diagnosed with breast, prostate and colorectal 
cancers. Other cancers with generally good prognoses, such as melanoma, also contributed a large proportion of the total 
(Table 7-6). 
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Cancers with generally poor survival, such as pancreatic and oesophageal cancer, represented fairly low numbers in the 
prevalent population (Table 7-7, 7-8). For example, out of almost 7,100 cases of pancreatic cancer diagnosed between 
1994 and 2012, only 7% (496) remain alive at the close of 2012.   
In contrast, there were much greater numbers of patients still alive who had been diagnosed with comparatively rarer 
cancers with good prognoses, such as thyroid cancer where 19-year prevalence to 2012 was 79% (Table 7-9).  
Over 70% of living prostate, colorectal and bladder cancer patients were over 65 at the end of 2012, reflecting their 
generally older age at diagnosis. In contrast, fewer than 15% of patients diagnosed with cancers of the cervix (Table 7-11) 
and Hodgkin lymphoma (Table 7-12) were over 65, indicative of their much younger age at diagnosis. 
 
Table 7-2. Prevalence of cancer of the lung in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 1,808 14 1,580 21 1,242 30 1,006 39 527 60 
male 1,859 10 1,587 15 1,292 24 1,026 31 591 53 
‡<65  1,200 14 1,090 21 896 32 732 42 396 68 
‡65+ 2,467 11 2,077 16 1,638 24 1,300 31 722 52 
Total 3,667 11 3,167 17 2,534 26 2,032 34 1,118 56 
‡ refers to age category of patient at end of 2012 
 
Table 7-3. Prevalence colorectal cancer in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 6,657 42 4,845 54 3,063 65 2,070 73 806 84 
male 8,205 39 6,374 54 4,160 66 2,826 74 1,166 87 
‡<65  4,213 49 3,592 64 2,524 76 1,790 83 746 94 
‡65+ 10,649 38 7,627 50 4,699 61 3,106 69 1,226 82 
Total 14,862 40 11,219 54 7,223 66 4,896 74 1,972 86 
‡ refers to age category of patient at end of 2012 
 
Table 7-4. Prevalence of breast cancer in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 27,099 67 19,724 81 11,994 89 7,531 93 2,661 97 
male 172 58 139 73 98 86 71 92 33 97 
‡<65  14,828 76 11,943 88 7,738 95 4,997 97 1,785 99 
‡65+ 12,443 59 7,920 71 4,354 81 2,605 87 909 94 
Total 27,271 67 19,863 81 12,092 89 7,602 93 2,694 97 
‡ refers to age category of patient at end of 2012 
 
Table 7-5. Prevalence of prostate cancer in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
‡<65  5,999 87 5,826 93 4,514 97 3,261 98 1,232 100 
‡65+ 19,359 58 15,977 76 9,173 86 5,743 91 1,846 96 
Total 25,358 63 21,803 80 13,687 90 9,004 93 3,078 97 
‡ refers to age category of patient at end of 2012 
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Table 7-6. Prevalence of melanoma of the skin in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 4,738 77 3,277 84 1,995 91 1,313 94 423 97 
male 2,842 66 2,188 75 1,383 83 954 91 330 96 
‡<65  4,162 84 3,102 89 1,923 93 1,284 96 414 98 
‡65+ 3,418 62 2,363 72 1,455 80 983 89 339 95 
Total 7,580 72 5,465 81 3,378 87 2,267 93 753 97 
‡ refers to age category of patient at end of 2012 
 
Table 7-7. Prevalence of cancer of the pancreas in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 269 7 220 11 179 17 150 25 99 46 
male 227 6 204 10 176 16 149 22 79 39 
‡<65  191 10 173 15 147 24 122 34 66 63 
‡65+ 305 6 251 8 208 13 177 19 112 36 
Total 496 7 424 10 355 16 299 23 178 42 
‡ refers to age category of patient at end of 2012 
 
Table 7-8. Prevalence of cancer of oesophagus in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 318 14 256 21 197 32 146 39 84 62 
male 552 15 481 23 373 34 296 45 157 69 
‡<65  317 19 284 28 224 42 176 55 98 81 
‡65+ 553 13 453 19 346 30 266 37 143 59 
Total 870 15 737 22 570 34 442 43 241 67 
‡ refers to age category of patient at end of 2012 
 
Table 7-9. Prevalence of cancer of the thyroid in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 1,295 83 1,016 90 680 93 474 96 162 98 
male 360 67 285 77 181 85 126 87 45 98 
‡<65  1,316 92 1,057 95 711 97 498 97 170 99 
‡65+ 339 51 244 63 150 71 102 80 37 93 
Total 1,655 79 1,301 87 861 91 600 94 207 98 
‡ refers to age category of patient at end of 2012 
 
Table 7-10. Prevalence of cancer of the bladder in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 1,014 42 628 50 319 54 211 60 99 83 
male 2,362 41 1,529 53 853 63 587 72 221 86 
‡<65  811 62 582 70 330 77 220 81 77 88 
‡65+ 2,565 37 1,575 48 842 56 578 65 243 84 
Total 3,376 41 2,157 52 1,172 61 798 68 320 85 
‡ refers to age category of patient at end of 2012 
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Table 7 11. Prevalence of cancer of the cervix in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
‡<65  2,338 70 1,711 77 1,070 84 679 89 207 91 
‡65+ 394 43 197 45 114 55 77 65 31 86 
Total 2,732 64 1,908 72 1,184 80 756 85 238 90 
‡ refers to age category of patient at end of 2012 
 
Table 7-11. Prevalence of Hodgkin lymphoma in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 687 79 442 86 261 88 170 91 44 88 
male 806 78 525 84 312 90 197 95 69 97 
‡<65  1,320 87 844 92 504 95 322 98 94 99 
‡65+ 173 45 123 54 69 63 45 69 19 73 
Total 1,493 79 967 85 573 90 367 93 113 93 
‡ refers to age category of patient at end of 2012 
 
Table 7-12. Prevalence of cancer of mouth and pharynx in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 733 47 573 60 373 69 263 75 88 85 
male 1,222 35 960 48 656 60 475 69 198 84 
‡<65  1,091 48 930 62 644 73 473 80 188 91 
‡65+ 864 32 603 42 385 52 265 60 98 74 
Total 1,955 39 1,533 52 1,029 63 738 71 286 84 
‡ refers to age category of patient at end of 2012 
 
Table 7-13. Prevalence of cancer of stomach in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 565 17 431 25 313 36 234 46 108 64 
male 914 17 746 26 542 36 411 45 178 63 
‡<65  456 20 392 32 298 44 224 55 93 73 
‡65+ 1,023 16 785 23 557 33 421 42 193 59 
Total 1,479 17 1,177 26 855 36 645 45 286 63 
‡ refers to age category of patient at end of 2012 
 
Table 7-14. Prevalence of cancer of the corpus uteri in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
‡<65  1,334 77 1,114 83 783 90 510 93 191 97 
‡65+ 2,007 60 1,250 69 735 78 468 84 178 90 
Total 3,341 66 2,364 75 1,518 84 978 88 369 94 
‡ refers to age category of patient at end of 2012 
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Table 7-15. Prevalence of cancer of the ovary in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
‡<65  1,058 41 811 55 541 69 377 79 156 94 
‡65+ 795 24 534 30 340 39 249 47 122 67 
Total 1,853 32 1,345 41 881 53 626 62 278 80 
‡ refers to age category of patient at end of 2012 
 
Table 7-16. Prevalence of cancer of the kidney in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 1,168 50 890 60 572 71 387 78 148 87 
male 1,824 45 1,427 56 980 68 665 74 266 85 
‡<65  1,427 59 1,165 70 807 78 554 82 238 91 
‡65+ 1,565 39 1,152 49 745 61 498 69 176 80 
Total 2,992 47 2,317 58 1,552 69 1,052 76 414 86 
‡ refers to age category of patient at end of 2012 
 
Table 7-17. Prevalence of malignant cancer of the brain in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 477 22 339 28 239 37 183 44 85 65 
male 599 20 439 26 314 35 243 46 132 69 
‡<65  898 29 648 38 453 50 336 61 158 81 
‡65+ 178 8 130 11 100 16 90 23 59 47 
Total 1,076 21 778 26 553 36 426 45 217 68 
‡ refers to age category of patient at end of 2012 
 
Table 7-18. Prevalence of benign cancer of the brain and CNS in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 1,219 76 790 82 466 90 297 93 100 97 
male 551 77 329 86 192 92 126 95 41 95 
‡<65  1,009 92 669 96 405 99 273 99 89 99 
‡65+ 761 62 450 69 253 81 150 85 52 93 
Total 1,770 76 1,119 83 658 91 423 94 141 97 
‡ refers to age category of patient at end of 2012 
 
Table 7-19. Prevalence of lymphoma in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 3,017 57 2,157 67 1,308 75 852 79 297 86 
male 3,347 54 2,456 65 1,502 73 1,010 78 378 86 
‡<65  3,781 70 2,723 80 1,678 87 1,112 90 400 95 
‡65+ 2,583 42 1,890 53 1,132 61 750 65 275 76 
Total 6,364 55 4,613 66 2,810 74 1,862 78 675 86 
‡ refers to age category of patient at end of 2012 
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Table 7-20. Prevalence of non- Hodgkin lymphoma in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 2,330 52 1,715 64 1,047 72 682 76 253 86 
male 2,541 49 1,931 62 1,190 70 813 74 309 84 
‡<65  2,461 64 1,879 76 1,174 84 790 88 306 94 
‡65+ 2,410 42 1,767 53 1,063 60 705 65 256 76 
Total 4,871 50 3,646 63 2,237 71 1,495 75 562 85 
‡ refers to age category of patient at end of 2012 
 
Table 7-21. Prevalence of multiple myeloma in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 2,330 52 1,715 64 1,047 72 682 76 253 86 
male 2,541 49 1,931 62 1,190 70 813 74 309 84 
‡<65  2,461 64 1,879 76 1,174 84 790 88 306 94 
‡65+ 2,410 42 1,767 53 1,063 60 705 65 256 76 
Total 4,871 50 3,646 63 2,237 71 1,495 75 562 85 
‡ refers to age category of patient at end of 2012 
 
Table 7-22. Prevalence of leukaemia in Ireland at the end of 2012 
 19 year 10 years 5 years 3 years 1 year 
 diagnosed 
from Jan 1994 
diagnosed 
from Jan 2003 
diagnosed 
from Jan 2008 
diagnosed 
from Jan 2010 
diagnosed 
during 2012 
 alive % alive alive % alive alive % alive alive % alive alive % alive 
female 1,425 44 1,011 56 604 66 378 71 136 79 
male 2,023 43 1,525 56 897 67 567 72 201 82 
‡<65  1,860 61 1,351 73 821 81 524 83 184 90 
‡65+ 1,588 32 1,185 44 680 55 421 61 153 71 
Total 3,448 43 2,536 56 1,501 67 945 72 337 80 
‡ refers to age category of patient at end of 2012 
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8. TREATMENT 
 
Since the establishment of the National Cancer Registry, cancer treatment has been recorded for each registered patient. 
Surgery, radiotherapy, chemotherapy (including immunotherapy) and hormone therapy data are presented here in 
summary format, i.e. did patients receive treatment between one month before and one year after diagnosis, which 
approximately coincides with the first course of treatment for most cancers. Surgery was defined as ‘tumour-directed 
surgery’ if it entailed tumour resection or other physical destruction, regardless of curative intent. Treatments or other 
procedures purely or mainly aimed at symptom relief were excluded if they did not also involve excision or destruction of 
tumour tissue. 
 
TREATMENT BY MODALITY, SITE AND DIAGNOSTIC PERIOD 
 
During the period 2004-2012, 48% of all invasive cancers (excluding NMSC) had tumour-directed surgery, 31% 
chemotherapy, 33% radiotherapy and 24% no tumour-directed treatment during the window of one month before 
diagnosis, and one year after diagnosis. However the proportion of cases that received each treatment varied 
considerably by cancer type (Figure 8-1). Equivalent figures for 1995-2003 are also shown in Figure 8-1. 
As expected rates of tumour-directed surgery was highest for solid tumours. During 2004-2012, over 70% of colorectal, 
breast, corpus uterine, testicular, bladder and thyroid cancers and melanoma had surgery either to completely remove or 
to reduce the tumour (highest 97% for testis). Rates of surgery were low (<25%) for cancers such as pancreas, lung and 
oesophagus where either the tumour site can prove difficult to operate on or patients frequently present with late-stage 
cancers.  
The highest rates of radiotherapy were found for cancers of the breast, mouth & pharynx, rectum, oesophagus, cervix and 
brain & CNS.  
Chemotherapy rates were highest for cancers of the blood and lymphatic systems but also for cancers of the ovary, 
rectum and breast (all >45%).  
Hormonal therapy was administered to substantial numbers of patients with breast and prostate cancer, where at least 
53% and 33% were treated during 2004-2012 (Figure 8-2). Note that, because hormonal therapy is sometimes 
administered on an outpatient basis, or the date on which hormonal therapy began is not always known, the figures 
presented on hormonal therapy should be regarded as conservative estimates.  
A substantial proportion of patients with some cancers had no tumour-directed treatment, although many of these 
patients had other procedures, such as palliative treatment to relieve symptoms. For example, 36% of lung cancer 
patients and 61% of pancreatic cancer patients during 2004-2012 had no tumour-directed therapy. Watchful waiting for 
some cancers may result in apparently high percentages of untreated cases, as was the case for leukaemia, where overall 
51% were classed as untreated. However, the majority of these cases were chronic lymphocytic subtypes where watchful 
waiting is a recognized management. Watchful waiting is also a common management for prostate cancers and 24% of 
these patients were also classified as untreated during 2004-2012.  
While overall rates of surgery for all cancers were 48% during both 1995-2003 and in 2004-2012, increases in the rate of 
surgery were observed for several individual cancer types between the earlier and later periods. Notable increases in the 
proportions of patients undergoing surgery were observed for lung (13% to 16%) and pancreatic cancer patients (8% to 
13%) and ovary (56% to 64%). However, a decline in the rate of surgery was observed for some sites between the two 
periods, notably a reduction in the proportion of prostate (42% to 27%) and lymphoma (12% to 9%) having surgery. 
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Figure 8-1. percentage of cancer patients that received tumour-directed treatment: 1995-2003, 2004-2012 
surgery radiotherapy chemotherapy no tumour-directed treatment 
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Rates of radiotherapy showed more substantial increases between the two periods than observed for surgery. Overall 
rates of radiotherapy increased from 26% to 33% (all cancers combined). However the proportion of patients having 
radiotherapy declined in the case of testicular cancer (39% to 24%) and Hodgkin lymphoma (42% to 27%) (Figure 8-1). The 
greatest relative increases in the proportion of patients treated with radiotherapy were observed for cancers of the 
prostate (19% to 40%), breast (56% to 67%), brain & CNS (43% to 59%), rectum (33% to 47%), stomach (9% to 14%), 
bladder (11% to 16%) and thyroid (37% to 44%). 
Use of chemotherapy increased overall from 23% to 31% of patients between 1995-2003 and 2004-2012 (Figure 8-1). The 
most substantial increases in relative terms were observed in patients with cancers of the corpus uteri (6% to 14%), 
kidney (8% to 15%), bladder (10% to 22%), brain/CNS (11% to 29%), pancreas (12% to 31%) , mouth/pharynx (13% to 
32%), lung (17% to 33%), stomach (15% to 36%), cervix (25% to 39%), oesophagus (26% to 42%) and rectum (35% to 52%).  
 
The proportion of breast cancer patients known to 
have had hormone therapy increased from 46% to 
53% between the periods 1995-2003 and 2004-2012. 
In contrast the proportion of prostate cancer 
patients that had hormone therapy decreased from 
39% to 33% (Figure 8-2). However, note the earlier 
caveat about completeness of hormonal therapy 
data. 
 
 
 
 
The proportion of patients that had no tumour-directed therapy dropped from 30% to 24% overall between 1995-2003 
and 2004-2012 (Figure 8-1). This decline was observed for almost all cancer sites, with notable relative changes observed 
for colon, rectum, melanoma, thyroid, lung, oesophagus, stomach, pancreas and brain/CNS.  
 
 
 
 
  
Figure 8-2.  
Percentage of cancer patients that received 
hormone therapy as part of treatment regimen:  
female breast and prostate cancer: 1995-2003 and 2004-2012 
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TREATMENT BY AGE, SEX AND CANCER SITE 
 
Figure 8-3. Percentage treated by age and sex:  
all invasive cancer (excluding NMSC): 2007-2011 
 Figure 8-4. Percentage treated by age and sex:  
mouth and pharynx cancer 2007-2011 
 
 
 
 
Over the five-year period 2007-2011, the effect of age (<65 vs. 65+) and sex on the proportion of all cancer patients who 
had surgery, radiotherapy, chemotherapy, and hormone therapy was explored (Figure 8-3). The same analyses were 
repeated for each of the main cancer sites individually (Figures 8-2 to 8-28). Note that treatments presented in Figures 8-
2 to 8-28 are not mutually exclusive, and many patients had combination treatment (cf. Figures 8.29 to 8.33). 
In general, considering all invasive cancers, males were less likely to receive treatment than females (especially among 
the under-65s), but this reflects differences in the types of cancer involved. Many prostate cancer patients are subject to 
watchful waiting (c.20-25%), while the vast majority of breast cancer patients had some form of treatment (c.95%). These 
two cancers alone account for about 30% of male and 30% of female cancers, respectively. Older patients (≥65 years) 
were less likely to receive treatment (except for hormone therapy) (Figure 8-3); this partly reflects the tolerability of 
treatments, especially with regard to chemotherapy and surgery, but may also reflect comorbidities or other factors 
influencing treatment decisions (Figure 8-3). ‘No treatment’ referred to no tumour-directed treatment; most patients 
listed under ‘no treatment’ would have had other forms of treatments aimed at symptom relief / palliation.  
For cancer of the mouth and pharynx, the proportion of older patients who had chemotherapy, radiotherapy and surgery 
was substantially lower than that for the younger population (Figure 8-4). The proportion of females who had no tumour-
directed treatment was greater than that of males: 42% and 32% respectively. 
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Figure 8-5. Percentage treated by age and sex:  
cancer of the oesophagus 2007-2011 
 Figure 8-6. Percentage treated by age and sex:  
cancer of the stomach 2007-2011 
 
 
 
 
Surgery for cancer of the oesophagus is very invasive and older patients were less likely to have surgery. Radiotherapy 
was used as a treatment option regardless of age. Chemotherapy was twice as likely to be given as a treatment if the 
patient was younger (Figure 8-5). Patients with cancer of the stomach had a broadly similar pattern of treatment as those 
with cancer of the oesophagus, except that radiotherapy was much less frequently used (Figure 8-6).  
Figure 8-7. Percentage treated by age and sex: 
colorectal cancer  
 Figure 8-8. Percentage treated by age and sex:  
cancer of the colon 2007-2011 
 
 
 
 
Colon cancer was generally treated with colectomy or with local excision, and over 75% of patients had such surgery, 
regardless of age and sex. Chemotherapy was twice as likely to be used if the patient was younger. Approximately 15% of 
patients receive no tumour-directed treatment (Figure 8-8).  
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Figure 8-9. Percentage treated by age and sex:  
cancer of the rectum/rectosigmoid junction 2007-2011 
 Figure 8-10. Percentage treated by age and sex:  
cancer of the pancreas 2007-2011 
 
 
 
 
Cancer of the rectum was generally treated with mesorectal excision or local excision (>70% of patients). Unlike cancer of 
the colon, radiotherapy was used in up to 40-50% of patients (more so in males than females). Just over 10% of patients 
had no tumour-directed treatment; 14% of females and 10% of males (Figure 8-9). Only about 15% of pancreatic cancer 
patients had surgery (up to 30% if they were younger). Chemotherapy was the main treatment modality (about one third 
of cases, or almost two thirds if younger. 63% of females and 53% of males had no tumour-directed treatment (Figure 8-
10). 
Figure 8-11. Percentage treated by age and sex:  
cancer of the lung 2007-2011 
 Figure 8-12. Percentage treated by age and sex:  
melanoma skin cancer: 2007-2011 
 
 
 
 
For lung cancer, only 18% of females and 16% of males had surgery, mostly lobectomy or wedge resection for non-small-
cell lung cancer (NSCLC). Approximately 40% of patients had radiotherapy and 34% had chemotherapy. 36% of males and 
35% of females had no tumour-directed treatment (Figure 8-11). Melanoma skin cancer was treated almost exclusively 
with surgery (excision), with over 90% of patients treated (Figure 8-12). Chemotherapy (targeted immunotherapy) was 
used only for patients with late-stage melanoma. 
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Figure 8-13. Percentage treated by age:  
female breast cancer: 2007-2011 
 Figure 8-14. Percentage treated by age:  
cancer of the cervix: 2007-2011 
 
 
 
 
85% of female breast cancer patients had surgery (breast-conserving or mastectomy). Almost two thirds of breast cancers 
were treated with radiotherapy, half had chemotherapy and at least half hormone therapy. Only 4% had no tumour-
directed treatment (Figure 8-13). Two thirds of cervical cancer patients had surgery and just over half had radiotherapy. 
Older patients were half as likely to have surgery but more likely to have radiotherapy. Almost 40% of patients had 
chemotherapy. Only 4% of cervical cancer patients had no tumour-directed treatment (Figure 8-14). 
Figure 8-15. Percentage treated by age:  
cancer of the corpus uteri: 2007-2011 
 Figure 8-16. Percentage treated by age:  
cancer of the ovary: 2007-2011 
 
 
 
 
Almost 95% of patients had surgery for cancer of the uterus (corpus uteri) and almost 50% had radiotherapy. 
Chemotherapy was used in 15% of cases. Treatment varied little by age. Only 3% of patients had no tumour-directed 
treatment (figure 8-15). Two thirds of ovarian cancer patients had surgery (85% in <65 and 47% in 65+). Chemotherapy 
was the other main treatment modality (almost two thirds of patients). Radiotherapy was rarely given (3% only). 
Approximately 1 in 5 had no tumour-directed treatment, almost all of whom were 65+ years (Figure 8-16).  
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Figure 8-17. Percentage treated by age:  
cancer of the testis: 2007-2011 
 Figure 8-18. Percentage treated by age: 
 cancer of the prostate: 2007-2011 
 
 
 
 
More than 95% of patients with testicular cancer had surgery (orchiectomy). Just over 1 in 5 had radiotherapy. 
Chemotherapy was almost exclusively confined to the younger subset (<65), who comprise the bulk of patients. Only 2% 
had no tumour-directed treatment (Figure 8-17). One quarter of prostate cancer patients had surgery (prostatectomy or 
TURP). The rate of surgery in older males was approximately half that of younger males (18% and 38% respectively). 40% 
of patients had radiotherapy regardless of age. Hormone therapy was used in 32% of patients (20% in <65, and 40% in 
65+). 23% of patients had no tumour-directed treatment; most of these would have been followed up in watchful waiting 
(Figure 8-18).  
Figure 8-19. Percentage treated by age and sex:  
cancer of the kidney 2007-2011 
 Figure 8-20. Percentage treated by age and sex:  
cancer of the bladder 2007-2011 
 
 
 
 
Almost 70% of patients with kidney cancer had surgery (over 80% of under-65s, and just over 50% in the 65+ age-group). 
Radiotherapy was used in only 10% of patients, chemotherapy in 14-17% of patients. Approximately one quarter of 
patients had no tumour-directed treatment (Figure 8-19). Over 70% of patients with cancer of the bladder had surgery. 
Radiotherapy was used in the treatment of 17% of patients. Chemotherapy was used to treat approximately 25% of 
patients (Figure 8-20).  
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Figure 8-21. Percentage treated by age and sex:  
cancer of the brain & CNS 2007-2011 
 Figure 8-22. Percentage treated by age and sex:  
benign cancer of the brain & CNS:   2007-2011 
 
 
 
 
Approximately 47% of patients with a malignant brain tumour underwent surgery; more so if they were younger (>58%), 
and less so if they were older (c.30%). Radiotherapy was received by approximately 60%. Chemotherapy was used in 
approximately 30% of patients (c.40% in <65 and c.20% in 65+) (Figure 8-21). Surgery was a more frequently used 
treatment for benign brain tumours (about 55% of patients). Radiotherapy was used in only 5-6% of patients, and 
chemotherapy not used at all. 44% of females and 41% of males had no tumour-directed treatment for benign brain 
tumours (Figure 8-22).  
Figure 8-23. Percentage treated by age and sex: 
cancer of the thyroid:  2007-2011 
 Figure 8-24. Percentage treated by age and sex:  
lymphoma (all):  2007-2011 
 
 
 
 
Approximately 90% of thyroid cancer patients had surgery, and radiotherapy was used in approximately 50% of cases; 
chemotherapy was used in only 3-4% of cases (Figure 8-23). Lymphoma (all types) was rarely treated with surgery (c.10%). 
Almost 20% of patients had radiotherapy. Chemotherapy was used in approximately 70% of patients. The proportion of 
patients who had no tumour-directed treatments was 24% of females and 21% of males (Figure 8-24). 
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Figure 8-25. Percentage treated by age and sex:  
Hodgkin lymphoma:  2007-2011 
 Figure 8-26. Percentage treated by age and sex:  
non-Hodgkin lymphoma:  2007-2011 
 
 
 
 
The bulk of Hodgkin lymphoma cases occur in younger patients (<65). It was treated mostly by chemotherapy (85-91% of 
patients). Radiotherapy was used in a quarter of patients. Slightly more males had no tumour-directed treatment (11% 
and 9%, for males and females respectively) (Figure 8-25). Non-Hodgkin lymphoma cases were also treated mainly with 
chemotherapy (65-68%). Radiotherapy was used in 15-17% of cases. Surgery was employed in approximately 10% of 
patients. 27% of females and 23% of males had no tumour-directed treatment (Figure 8-26).  
Figure 8-27. Percentage treated by age and sex:  
multiple myeloma: 2007-2011 
 Figure 8-28. Percentage treated by age and sex:  
leukaemia: 2007-2011 
 
 
 
 
Multiple myeloma was treated mostly with chemotherapy, used in over 65% of all patients (66% in females, 70% in 
males). Radiotherapy was used in about one quarter of patients. 26% of females and 22% of males had no tumour-
directed treatment (Figure 8-27). Approximately half of patients with leukaemia were treated with chemotherapy (but 
c.70% of patients <65 years and c.30% of 65+). Half of patients had no tumour-directed treatment (48% of males and 50% 
of females) (Figure 8-28).   
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TREATMENT: COMBINATION REGIMENS BY SELECTED SITES 
 
Most cancer treatments are not administered in isolation; rather they are given as part of a regimen with the aim of 
achieving therapeutic synergism. In this section, the use of broad treatment modalities (surgery, radiotherapy, 
chemotherapy and hormone therapy), separately or in various combinations, is summarised for cancers of the breast, 
prostate, lung, colon and rectum. 
 
 
Throughout 1996-2011 the proportion of breast cancer patients who received treatment regimens with a surgical 
component remained fairly constant at around 80-85% (Figure 8-29). However, the proportion receiving radiotherapy 
(either before/after surgery or without surgery) changed substantially, from 46% in 1996 to 70% in 2011. The most 
commonly administered combination regimens for breast cancer in 2011 were surgery + chemotherapy + radiotherapy 
(SCR) (18%), SCR with hormone therapy (SCRH) (21%), the same combination bar chemotherapy (SRH) (18%), and surgery 
+ radiotherapy (SR) (10%). Radiotherapy as sole modality was used for only 1% of patients (Figure 8-29).  
The use of chemotherapy as part of a treatment regimen increased from 33% in 1996 to over 50% from 2002 onwards. In 
2011, it was mostly given in combination with surgery + radiotherapy (18%), surgery + radiotherapy + hormone therapy 
(21%). The use of chemotherapy as sole modality was noted for only 1% of patients (Figure 8-29).  
The use of hormone therapy as sole therapy or as part of combination therapy decreased from nearly 60% of patients in 
1996 to c.45% in 2003 and then increased again to nearly 60% in 2011. Fewer than 10% of patients received hormone 
therapy as sole agent. It is mostly recommended as part of a combination regimen, and  in general these combinations 
increased over time - SCRH  from 9% of patients in 1996 to 21% in 2011, and SRH from 15% in 1996 to 18% in 2011 -
although the combination of surgery + hormone therapy decreased substantially from 20% in 1996 to only 5% in 2011. 
However, for reasons noted earlier, NCR data may have underestimated the full extent of hormone treatment in breast 
cancer (Figure 8-29).  
The proportion of breast cancer patients who had no tumour-directed treatment decreased from 6% in 1996 to 4% in 
2011.
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Figure 8-29. Percentage treated: breast cancer: mutually exclusive combination regimens: years 1996-2011 
emphasis: surgery (red) emphasis: radiotherapy (purple) 
  
emphasis: chemotherapy (blue) emphasis: hormone therapy (green) 
  
No TD Tx= no tumour-directed treatment  
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Treatment regimens for prostate cancer 
have changed substantially over the 
period 1996-2011 (Figure 8-30). Use of 
surgery as the sole treatment modality 
decreased from 40% in 1996 to 24% in 
2011. Overall use of surgery, including 
combination regimens, also decreased, 
from 56% to 28% over the same period. 
Yet, in 2011 the proportion that had 
surgery (only) still formed the largest 
group of patients (excluding those who 
had no tumour-directed treatment: 24%, 
most of whom were probably in watchful 
waiting). 
The most notable change has been the 
adoption of radiotherapy as part of the 
treatment regimen. In 2011, 43% of 
patients had radiotherapy, increased 
from only 9% in 1996.  19% of patients 
had radiotherapy as their sole treatment 
in 2011. Otherwise it was given with 
surgery (2%), or surgery and hormone 
therapy (1%), or with hormone therapy 
(20%) (Figure 8-30).  
Hormone therapy in the form of 
androgen deprivation is a cornerstone of 
prostate cancer treatment. The 
combination of hormone therapy and 
radiotherapy has emerged as the main 
non-surgical treatment regimen, utilised 
in only 2% of patients in 1996 but 20% in 
2011. This mirrors the decline of hormone 
therapy as sole treatment, from 17% to 
only 9% over the same period (Figure 8-
30). 
 
  
Figure 8-30. Percentage treated: prostate cancer: 
mutually exclusive combination regimens years 1996-2011 
emphasis: surgery (red) 
 
emphasis: radiotherapy (blue) 
 
emphasis: hormone therapy (green) 
 
No TD Tx= no tumour-directed treatment 
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In 2011, surgery-based regimens were used 
in only 19% of lung cancer patients; 12% 
where surgery was the sole treatment, 1% 
where it was used with radiotherapy, 3% 
with chemotherapy and 1% with both 
chemotherapy and radiotherapy. Surgery is 
not used in the subset of small-cell lung 
cancer (SCLC), which make up 
approximately 15% of lung cancer cases 
(Figure 8-31).  
Radiotherapy is an important treatment 
modality in lung cancer. Radiotherapy-
based regimens increased in use from 31% 
of cases in 1996 to 39% of cases in 2011. In 
2011 radiotherapy was the sole treatment 
in 19% of cases. Otherwise, it was 
administered with chemotherapy (18%), or 
with surgery (1%), or with surgery and 
chemotherapy (3%) (Figure 8-31). 
Chemotherapy-based regimens increased 
in use from 13% of cases in 1996 to 33% of 
cases in 2011. In 2011 chemotherapy was 
the sole treatment in 11% of cases. 
Otherwise, it was administered with 
radiotherapy (18%), or surgery (3%), or 
surgery and radiotherapy (2%) (Figure 8-
31). 
The proportion of patients who had no 
tumour-directed treatment decreased from 
53% in 1996 to 35% in 2011.  
  
Figure 8-31. Percentage treated: lung cancer: 
mutually exclusive combination regimens years 1996-2011 
emphasis: surgery (red) 
 
emphasis: radiotherapy (purple) 
 
emphasis: chemotherapy (blue) 
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Overall, c.77% of patients with colon 
cancer underwent a surgery-based 
treatment regimen in the period 1996-
2011 (Figure 8-3). In 2011, 50% of colon 
cancer cases had surgery as their sole 
treatment. Otherwise, surgery was 
given with chemotherapy (27%). 
Chemotherapy was the sole treatment 
in 7% of patients. The proportion of 
patients who had no tumour-directed 
treatment of the colon decreased from 
23% in 1996 to 15% in 2011. 
During 1996-2011, c.85% of patients 
with rectal/rectosigmoid cancer 
received a surgery-based treatment 
protocol. In 2011, 30% of patients had 
surgery as their sole treatment. 
Otherwise, they had surgery with 
chemotherapy and radiotherapy (27%), 
or with chemotherapy (12%), or with 
radiotherapy (Figure 8-33).  
Over the same period, the proportion 
of patients who had a radiotherapy-
based regimen increased from 22% to 
39%. In 2011, 27% of patients had 
radiotherapy with surgery and 
chemotherapy, or with surgery (5%), or 
with chemotherapy (4%), or they had 
radiotherapy as their sole treatment 
(4%) (Figure 8-33). 
The proportion of patients who had a 
chemotherapy-based regimen 
increased from 27% in 1996 to 48% in 
2011. In 2011, 27% of patient had 
chemotherapy with surgery and 
radiotherapy, or with surgery (12%), or 
with radiotherapy (4%), or they had 
chemotherapy as their sole treatment 
(6%) (Figure 8-33). 
  
Figure 8-32. Percentage treated: colon cancer:  
mutually exclusive combination regimens years 1996-2011 
 
No TD Tx= no tumour-directed treatment 
Figure 8-33. Percentage treated: rectum & rectosigmoid junction (RSJ):  
mutually exclusive combination regimens years 1996-2011 
emphasis: surgery (red) 
 
emphasis: radiotherapy (purple) 
 
emphasis: chemotherapy (blue) 
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9. SURVIVAL 
 
CANCER SURVIVAL IN IRELAND: 1994-2011 
 
Net survival of cancer patients can be 
interpreted as the proportion of patients 
who survive a specified time after 
diagnosis, after adjusting for other 
potential causes of death (background 
mortality). In effect, it estimates the 
likelihood of survival in the hypothetical 
situation in which there are no other 
causes of death (much like the more 
traditional relative survival). 
Considering all invasive cancers (excl. 
NMSC) together, net survival to five 
years after diagnosis increased from 
45% for Irish patients diagnosed during 
1994-1999 to 59% during 2006-2011 
(Figure 9-1). 
Compared with other invasive cancers 
occurring in both sexes, net survival at 
five years was notably high for 
melanoma skin cancer diagnosed during 
2006-2011 (86%). Other cancers with 
five-year survival >70% included 
Hodgkin lymphoma (83%), and thyroid 
(83%) and bladder cancers (73%). In 
contrast, survival was very low for 
pancreatic (9%), liver (12%), lung (15%), 
oesophageal (19%), stomach (25%) and 
malignant brain cancers (24%).  
Most cancers show ongoing 
improvements in survival. Of the non-
sex-specific cancers, relative 
improvements between 1994-1999 and 
2006-2011 were greatest for cancers of 
the pancreas (6% to 9%), lung (10% to 
15%), oesophagus (11% to 19%), 
stomach (17% to 25%), kidney (47% to 
58%), and rectum (48% to 60%), and for 
multiple myeloma (28% to 50%), 
leukaemia (46% to 59%) and non-
Hodgkin lymphoma (47% to 64%).  
  
Figure 9-1. Net survival at five years for main cancers in Ireland:  
1994-2011: males and females combined (age-standardised) 
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Figure 9-2. Net survival at five years for sex specific cancers:  1994-2011 
 
Females Males 
  
  
  
During 2006-2011, for the first time, five-year net survival for all cancers combined in males (59%) exceeded that of 
females (57%) (Figure 9-2). However, this comparison does not take account of differences between the sexes or changes 
over time in the relative frequency of different cancer types. In particular, recent survival figures for male cancers as a 
whole are strongly influenced by prostate cancer, which has shown major increases in both incidence and survival in the 
last two decades. 
For breast cancer, comparing the diagnosis periods 1994-1999 and 2006-2011, five-year net survival increased from 72% 
to 81%.  There was no improvement in survival for uterine cancer (corpus uteri), with estimates of 74% and 73% for the 
same periods. Survival for cancer of the cervix increased from 58% (1994-1999) to 63% (2006-2011). There was a very 
small increase in net survival for ovarian cancer, from 30% to 32% for the earlier and later periods respectively (Figure 
9.2).  
For male-specific cancers, cancer of the testis showed very high net survival, with an increase in five-year survival from 
90% to 96% between 1994-1999 and 2006-2011. For prostate cancer, there was a marked increase in five-year survival 
from 69% to 91% between the same periods (Figure 9.2). 
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CANCER SURVIVAL: INTERNATIONAL COMPARISON (CONCORD-2 STUDY, 2014)  
 
For the CONCORD-2 study, tumour records were submitted by 279 population-based cancer registries in 67 countries (5 
continents) for 25·7 million adults (age 15-99 years) and 75 000 children (age 0-14 years) diagnosed with cancer during 
1995-2009 and followed up to Dec 31, 2009. The main results, published in 2014, covered cancers of the stomach, colon, 
rectum, liver, lung, breast (women), cervix, ovary and prostate in adults, and adult and childhood leukaemia. A summary 
of five-year net survival estimates is presented below (Figures 9-1 to 9-6), specifically comparing Ireland with other 
European countries[14]. In general, across the 11 cancer types included in CONCORD-2, survival rates for Ireland fell 
towards the mid-range of European estimates. But there were some deviations from this, for example adult leukaemia 
(for which Ireland ranked about 6
th
 of 26 countries) and cervical cancer (23
rd
 of 26 countries). Survival from ovarian cancer 
in Ireland was the lowest of any European countries, but this might partly reflect coding differences between countries (it 
is possible that Irish figures included fewer ‘borderline’ malignancies, which would have better survival). 
 
Figure 9-3. Age-standardised net survival at 5 years (%) in Europe - CONCORD-2 [14] 
stomach colon & rectosigmoid junction 
  
years of 
 incidence 
Rank 
Ireland 
% absolute change 
2000-04/2005-09 
2000-04 18  
2005-09 18 4.0% 
 
years of 
 incidence 
Rank 
Ireland 
% absolute change 
2000-04/2005-09 
2000-04 14  
2005-09 14 5.0% 
 
  
13 
18 
18 
19 
19 
20 
21 
21 
23 
23 
23 
23 
23 
24 
25 
26 
27 
27 
28 
30 
32 
32 
32 
33 
33 
33 
11 
15 
16 
17 
16 
20 
22 
20 
19 
22 
21 
22 
21 
22 
26 
26 
26 
25 
27 
28 
30 
34 
32 
30 
30 
28 
0 10 20 30 40 50 60 70
Bulgaria…
Denmark
Malta
UK
Poland
Slovakia
Croatia
Netherlands
IRELAND
Estonia
Latvia
Czech republic
Sweden
Norway
Finland
Lithuania
Slovenia
Spain
France
Switzerland
Germany
Iceland
Italy
Portugal
Austria
Belgium
% 5-year net survival 
2000–04 
2005–09 
45 
47 
50 
50 
52 
52 
52 
54 
55 
56 
56 
56 
59 
59 
60 
60 
60 
62 
63 
63 
63 
63 
63 
65 
65 
65 
42 
44 
50 
46 
52 
49 
50 
51 
51 
52 
58 
53 
54 
56 
60 
58 
56 
58 
59 
61 
60 
60 
61 
64 
62 
61 
0 10 20 30 40 50 60 70
Latvia…
Bulgaria
Slovakia
Poland
Lithuania
Estonia
Croatia
UK
Czech republic
Denmark
Malta
Slovenia
IRELAND
Spain
France
Netherlands
Portugal
Norway
Sweden
Finland
Austria
Italy
Switzerland
Belgium
Germany
Iceland
% 5-year net survival 
2000–04 
2005–09 
Cancer in Ireland 1994-2012                                                Page 47 
 
Figure 9-4. Age-standardised net survival at 5 years (%) in Europe - CONCORD-2 [14] 
rectum & anus liver 
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Figure 9-5. Age-standardised net survival at 5 years (%) in Europe, by site - CONCORD-2 [14] 
lung female breast 
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Figure 9-6. Age-standardised net survival at 5 years (%) in Europe - CONCORD-2 [14] 
cervix ovary & uterine adnexa 
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Figure 9-7. Age-standardised net survival at 5 years (%) in Europe - CONCORD-2 [14] 
prostate leukaemia (adult) 
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Figure 9-8.  
Age-standardised net survival at 5 years (%) in Europe - CONCORD-2 [14] 
acute lymphoblastic leukaemia (children) 
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10. METHODS 
 
 
The National Cancer Registry was established by the Minister for Health in 1991. It has been collecting comprehensive 
cancer information for the Republic of Ireland since 1994. The information collected is used in research into the causes of 
cancer, in education and information programmes, and in the planning of cancer services to deliver the best cancer care 
to the whole population. Completeness of case ascertainment at five years after diagnosis is estimated to be at least 98% 
[6]. 
Incidence data are collected and coded by the NCR according to the ICD-O-3 classification (including translation from ICD-
O-2 codes for older data). For convenience, cancer types are specified or grouped in this report under ICD10-type codes, 
but these do not correspond to ‘strict’ ICD10 codes as some neoplasms classed as non-invasive / non-malignant under 
ICD10 (e.g. myelodysplastic syndrome, ICD10 D46) are now considered fully malignant under ICDO3. For such cases, the 
nearest equivalent malignant ICD10 code or subheading is used (thus polycythaemia vera, myelodysplastic syndromes 
and chronic myeloproliferative diseases have been included under C96, rather than D45-D47).  
Mortality data was provided by the Central Statistics Office (CSO) for 1994-2011 [15]. National anonymised datasets for 
all cancer deaths are provided to the Registry annually by the CSO. At the time of writing this report (December 2014), 
age-, sex- and cause-specific mortality data were not available for 2012. Therefore, mortality rates by cancer type were 
estimated for 2012 by extrapolation from mortality data for the preceding 10 years (2002-2011).  
The age-standardised (ASR) rate is the annual rate of newly diagnosed cases (or of deaths) in a given population (and 
year), expressed per 100,000 per persons, weighted by the age-structure of a defined ‘standard’ population, to allow 
meaningful comparisons geographically and over time. Age-standardised rates for incidence and mortality were weighted 
by the European standard population [16][17].  
Annual percentage changes (APC) of incidence and mortality over time (1994-2012) were estimated with the Joinpoint 
regression program, using annual age-standardised rates and their standard errors as inputs [18][19].  
The stage of disease at diagnosis was presented in summary form for each of the main cancer sites according to TNM 5
th
 
edition classification [20]. Stage data originally collected using TNM 4
th
 edition criteria (mainly pre-2000) was translated 
to 5
th
 edition codes as necessary. Where nodal status was coded as ‘NX’, ‘N0’ was assumed. Where metastasis status was 
coded as ‘MX’, ‘M0’ was assumed.  
Data was downloaded from the European Cancer Observatory (ECO) database to compare incidence and mortality 
(estimates) between Ireland and other European countries for the most common cancer sites in 2012 [3]. Published 
survival data from the CONCORD-2 study was extracted to compare 5-year net survival rates in Ireland against other 
European countries [14].  
The NCRI collects information on first course of treatment in cancer according to ICD9-CM (in earlier years) and ICD-10AM 
6
th
 edition coding (more recently) [21][22]. Tumour-directed surgery (including endoscopic tumour-directed surgery, or 
other tumour destructive procedure) was counted if undertaken 1 month before, and up to 12 months after diagnosis. A 
case was deemed to have had chemotherapy or hormone therapy (e.g. tamoxifen) if at least one medical oncology agent 
(including targeted immunotherapy or other targeted treatment) was administered over the same time frame. Similarly, a 
case was deemed to have undergone radiotherapy if the case underwent at least one radiotherapy session. Treatments 
not fitting these criteria (e.g. symptom-relieving surgery and palliative care) were not considered as tumour-directed 
treatment, i.e. if they did not remove or destroy (or slow growth of) tumour tissue.  
Survival figures presented in this report use net survival, an 'improved' version of relative survival (which was presented 
in previous NCR reports) taking better account of competing mortality risks and allowing greater comparability between 
different populations or age-groups. Net survival represents the cumulative probability of a patient surviving a given time 
in the hypothetical situation in which the disease of interest is the only possible cause of death, i.e. survival having 
controlled for other possible cause of death. (This involves comparison of observed survival with the expected survival of 
Cancer in Ireland 1994-2012                                                Page 53 
 
persons of the same age and gender in the general population, as for relative survival.) Net survival was calculated using 
the ‘strs’ command in STATA with an adjustment to obtain the Pohar-Perme estimate [23][24]. All survival estimates were 
age-standardisation to the International Cancer Survival Standards (ICSS) [25]. Net survival to five years was presented for 
the most frequently occurring cancers.  
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12. APPENDIX I: SUMMARY TABLE-CANCER INCIDENCE: 2010-2012 
 
ICD10 cancer site (INCIDENCE) FEMALES MALES TOTAL 
ASR†: age-standardised rate, cases per 100,000 
(standardised to the European population) 
annual  
average 
2010-2012 
% all 
invasive  
% all 
invasive 
excl. 
NMSC 
ASR† cumulative 
risk (%) to  
age 75y  
annual  
average 
2010-2012 
% all 
invasive  
% all 
invasive 
excl. 
NMSC 
ASR† cumulative 
risk (%) to  
age 75y  
annual  
average 
2010-2012 
% all invasive  % all invasive 
excl.  
NMSC 
C00-C96: All invasive cancers*    13,378  100.0%  543.9 35.04   15,788  100.0%  722.1 44.22   29,166  100.0%  
C00-C43, C45-C96: All invasive cancers, excluding NMSC*     9,312  69.6% 100.0% 384.5 26.55   10,751  68.1% 100.0% 492.5 33.63   20,063  68.8% 100.0% 
D00-D48: All non-invasive neoplasms**     5,110  - - 203.0 14.18    1,497  - - 68.0 5.26    6,606  - - 
C00-D48: All registered neoplasms    18,488  - - 746.9 44.25   17,284  - - 790.1 47.15   35,772  - - 
C00: lip        5  <0.1% 0.1% 0.2 0.01      15  0.1% 0.1% 0.7 0.05      20  0.1% 0.1% 
C01: base of tongue        8  0.1% 0.1% 0.4 0.04      27  0.2% 0.3% 1.3 0.11      35  0.1% 0.2% 
C02: other tongue       26  0.2% 0.3% 1.1 0.09      43  0.3% 0.4% 2.0 0.17      69  0.2% 0.3% 
C03: gum        9  0.1% 0.1% 0.4 0.03       8  0.1% 0.1% 0.4 0.04      17  0.1% 0.1% 
C04: floor of mouth        7  <0.1% 0.1% 0.3 0.03      21  0.1% 0.2% 1.0 0.10      28  0.1% 0.1% 
C05: palate        8  0.1% 0.1% 0.3 0.03      11  0.1% 0.1% 0.5 0.05      19  0.1% 0.1% 
C06: other mouth       16  0.1% 0.2% 0.6 0.04      17  0.1% 0.2% 0.8 0.06      33  0.1% 0.2% 
C07: parotid       14  0.1% 0.2% 0.6 0.05      15  0.1% 0.1% 0.7 0.05      29  0.1% 0.1% 
C08: other salivary        5  <0.1% 0.1% 0.2 0.01       3  <0.1% <0.1% 0.1 0.01       8  <0.1% <0.1% 
C09: tonsil       12  0.1% 0.1% 0.6 0.05      38  0.2% 0.4% 1.8 0.16      50  0.2% 0.2% 
C10: oropharynx        4  <0.1% <0.1% 0.2 0.02      16  0.1% 0.1% 0.7 0.06      20  0.1% 0.1% 
C11: nasopharynx        5  <0.1% 0.1% 0.2 0.02      14  0.1% 0.1% 0.7 0.06      19  0.1% 0.1% 
C12: pyriform        4  <0.1% <0.1% 0.2 0.02      20  0.1% 0.2% 0.9 0.09      24  0.1% 0.1% 
C13: hypopharynx        5  <0.1% 0.1% 0.2 0.01      13  0.1% 0.1% 0.6 0.05      18  0.1% 0.1% 
C14: other mouth/pharynx        5  <0.1% 0.1% 0.2 0.02      11  0.1% 0.1% 0.5 0.05      17  0.1% 0.1% 
C01-C14: mouth & pharynx      129  1.0% 1.4% 5.5 0.45     257  1.6% 2.4% 11.9 1.05     386  1.3% 1.9% 
C15: oesophagus      139  1.0% 1.5% 5.2 0.39     247  1.6% 2.3% 11.4 0.94     386  1.3% 1.9% 
C16: stomach      187  1.4% 2.0% 7.0 0.48     344  2.2% 3.2% 15.7 1.23     530  1.8% 2.6% 
C17: small intestine       29  0.2% 0.3% 1.2 0.09      40  0.3% 0.4% 1.8 0.15      70  0.2% 0.3% 
C18: colon      718  5.4% 7.7% 27.6 2.03     861  5.5% 8.0% 39.1 2.89    1,579  5.4% 7.9% 
C19: rectosigmoid       65  0.5% 0.7% 2.6 0.22     113  0.7% 1.1% 5.2 0.41     178  0.6% 0.9% 
C20: rectum      237  1.8% 2.5% 9.7 0.80     445  2.8% 4.1% 20.4 1.69     682  2.3% 3.4% 
C21: anus       26  0.2% 0.3% 1.1 0.08      20  0.1% 0.2% 0.9 0.06      46  0.2% 0.2% 
C18-C21: colorectal     1,046  7.8% 11.2% 41.1 3.11    1,439  9.1% 13.4% 65.6 4.97    2,486  8.5% 12.4% 
C22: liver       74  0.6% 0.8% 2.8 0.21     144  0.9% 1.3% 6.5 0.52     217  0.7% 1.1% 
C23: gallbladder       33  0.2% 0.4% 1.2 0.09      13  0.1% 0.1% 0.6 0.04      46  0.2% 0.2% 
C24: other biliary       47  0.4% 0.5% 1.7 0.11      56  0.4% 0.5% 2.5 0.19     103  0.4% 0.5% 
C25: pancreas      228  1.7% 2.5% 8.6 0.63     255  1.6% 2.4% 11.7 0.91     484  1.7% 2.4% 
C26: other digestive       18  0.1% 0.2% 0.6 0.03      16  0.1% 0.1% 0.7 0.05      33  0.1% 0.2% 
C30: nasal cavity/middle ear        6  <0.1% 0.1% 0.3 0.02       8  0.1% 0.1% 0.4 0.03      14  <0.1% 0.1% 
C31: sinuses        4  <0.1% <0.1% 0.1 0.01       7  <0.1% 0.1% 0.3 0.02      10  <0.1% 0.1% 
C32: larynx       21  0.2% 0.2% 0.9 0.08     142  0.9% 1.3% 6.7 0.57     164  0.6% 0.8% 
C33: trachea        1  <0.1% <0.1% 0.0 <0.01       1  <0.1% <0.1% 0.1 <0.01       3  <0.1% <0.1% 
C34: lung      973  7.3% 10.4% 39.0 3.18    1,300  8.2% 12.1% 59.3 4.55    2,273  7.8% 11.3% 
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ICD10 cancer site (INCIDENCE) FEMALES MALES TOTAL 
ASR†: age-standardised rate, cases per 100,000 
(standardised to the European population) 
annual  
average 
2010-2012 
% all 
invasive  
% all 
invasive 
excl. 
NMSC 
ASR† cumulative 
risk (%) to  
age 75y  
annual  
average 
2010-2012 
% all 
invasive  
% all 
invasive 
excl. 
NMSC 
ASR† cumulative 
risk (%) to  
age 75y  
annual  
average 
2010-2012 
% all invasive  % all invasive 
excl.  
NMSC 
C37: thymus        4  <0.1% <0.1% 0.2 0.02       4  <0.1% <0.1% 0.2 0.02       8  <0.1% <0.1% 
C38: mediastinum        6  <0.1% 0.1% 0.2 0.02      10  0.1% 0.1% 0.4 0.03      16  0.1% 0.1% 
C39: other chest        <0.1% <0.1% 0.0 <0.01  <0.1% <0.1% 0.0 <0.01       -   <0.1% <0.1% 
C40: bones, joints of limbs        9  0.1% 0.1% 0.4 0.03      13  0.1% 0.1% 0.6 0.05      22  0.1% 0.1% 
C41: bones, joints head and trunk        6  <0.1% 0.1% 0.3 0.02      10  0.1% 0.1% 0.4 0.03      16  0.1% 0.1% 
C43: melanoma skin      496  3.7% 5.3% 20.5 1.64     392  2.5% 3.6% 17.8 1.42     889  3.0% 4.4% 
C44: non-melanoma skin (NMSC)     4,066  30.4%  159.4 11.55    5,036  31.9%  229.7 15.96    9,102  31.2%  
C45: mesothelioma        7  <0.1% 0.1% 0.3 0.03      32  0.2% 0.3% 1.5 0.12      39  0.1% 0.2% 
C46: Kaposi's sarcoma        1  <0.1% <0.1% 0.0 <0.01       8  0.1% 0.1% 0.4 0.03       9  <0.1% <0.1% 
C47: peripheral nerves        3  <0.1% <0.1% 0.1 0.01       3  <0.1% <0.1% 0.1 0.01       6  <0.1% <0.1% 
C48: peritoneum       16  0.1% 0.2% 0.7 0.06       5  <0.1% <0.1% 0.2 0.01      21  0.1% 0.1% 
C49: connective tissues       39  0.3% 0.4% 1.6 0.13      56  0.4% 0.5% 2.5 0.17      95  0.3% 0.5% 
C50: breast     2,816  21.1% 30.2% 122.7 9.64      28  0.2% 0.3% 1.3 0.10    2,844  9.8% 14.2% 
C51: vulva       49  0.4% 0.5% 1.9 0.14           49  0.2% 0.2% 
C52: vagina       11  0.1% 0.1% 0.5 0.04           11  <0.1% 0.1% 
C53: cervix      306  2.3% 3.3% 13.0 1.01          306  1.0% 1.5% 
C54: corpus uteri      412  3.1% 4.4% 17.9 1.61          412  1.4% 2.1% 
C55: uterus, NOS       26  0.2% 0.3% 1.1 0.09           26  0.1% 0.1% 
C56: ovary      360  2.7% 3.9% 15.1 1.23          360  1.2% 1.8% 
C57: other female genital       14  0.1% 0.2% 0.6 0.04           14  <0.1% 0.1% 
C58: placenta        3  <0.1% <0.1% 0.1 0.01            3  <0.1% <0.1% 
C60: penis           30  0.2% 0.3% 1.3 0.09      30  0.1% 0.1% 
C61: prostate         3,384  21.4% 31.5% 157.3 13.83    3,384  11.6% 16.9% 
C62: testis          176  1.1% 1.6% 7.3 0.52     176  0.6% 0.9% 
C63: other male genital            3  <0.1% <0.1% 0.1 0.01       3  <0.1% <0.1% 
C64: kidney      191  1.4% 2.1% 7.9 0.69     351  2.2% 3.3% 16.1 1.31     542  1.9% 2.7% 
C65: renal pelvis        9  0.1% 0.1% 0.4 0.03      13  0.1% 0.1% 0.6 0.05      22  0.1% 0.1% 
C66: ureter        7  0.1% 0.1% 0.3 0.02      11  0.1% 0.1% 0.5 0.04      18  0.1% 0.1% 
C67: bladder      129  1.0% 1.4% 4.7 0.33     314  2.0% 2.9% 14.3 1.00     443  1.5% 2.2% 
C68: other urinary        2  <0.1% <0.1% 0.1 <0.01       3  <0.1% <0.1% 0.1 0.01       5  <0.1% <0.1% 
C69: eye       24  0.2% 0.3% 1.0 0.08      28  0.2% 0.3% 1.3 0.12      52  0.2% 0.3% 
C70: meninges        8  0.1% 0.1% 0.3 0.02       5  <0.1% <0.1% 0.2 0.01      13  <0.1% 0.1% 
C71: brain      149  1.1% 1.6% 6.3 0.51     193  1.2% 1.8% 8.7 0.71     342  1.2% 1.7% 
C72: spinal cord        7  <0.1% 0.1% 0.3 0.02       4  <0.1% <0.1% 0.2 0.01      11  <0.1% 0.1% 
C73: thyroid      182  1.4% 2.0% 7.8 0.63      58  0.4% 0.5% 2.6 0.21     240  0.8% 1.2% 
C74: adrenal        8  0.1% 0.1% 0.3 0.02      10  0.1% 0.1% 0.4 0.03      18  0.1% 0.1% 
C75: other endocrine        6  <0.1% 0.1% 0.2 0.01       9  0.1% 0.1% 0.4 0.04      15  0.1% 0.1% 
C76: ill-defined site       15  0.1% 0.2% 0.5 0.04       9  0.1% 0.1% 0.4 0.04      24  0.1% 0.1% 
C77: lymph nodes        2  <0.1% <0.1% 0.1 <0.01       2  <0.1% <0.1% 0.1 0.01       4  <0.1% <0.1% 
C80: unknown primary site      250  1.9% 2.7% 8.9 0.56     212  1.3% 2.0% 9.6 0.61     461  1.6% 2.3% 
C81: Hodgkin lymphoma       63  0.5% 0.7% 2.7 0.21      73  0.5% 0.7% 3.2 0.25     137  0.5% 0.7% 
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ICD10 cancer site (INCIDENCE) FEMALES MALES TOTAL 
ASR†: age-standardised rate, cases per 100,000 
(standardised to the European population) 
annual  
average 
2010-2012 
% all 
invasive  
% all 
invasive 
excl. 
NMSC 
ASR† cumulative 
risk (%) to  
age 75y  
annual  
average 
2010-2012 
% all 
invasive  
% all 
invasive 
excl. 
NMSC 
ASR† cumulative 
risk (%) to  
age 75y  
annual  
average 
2010-2012 
% all invasive  % all invasive 
excl.  
NMSC 
C82: follicular non-Hodgkin lymphoma (NHL)       89  0.7% 1.0% 3.9 0.34      85  0.5% 0.8% 3.9 0.32     173  0.6% 0.9% 
C83: diffuse non-Hodgkin lymphoma      140  1.0% 1.5% 5.6 0.46     191  1.2% 1.8% 8.7 0.67     331  1.1% 1.6% 
C84: peripheral and cutaneous T cell lymphoma       21  0.2% 0.2% 0.9 0.07      36  0.2% 0.3% 1.7 0.13      57  0.2% 0.3% 
C85: other and unspecified NHL       74  0.6% 0.8% 3.0 0.24      87  0.6% 0.8% 3.9 0.30     162  0.6% 0.8% 
C82-C85: all non-Hodgkin lymphoma (NHL)      324  2.4% 3.5% 13.4 1.11     399  2.5% 3.7% 18.2 1.42     723  2.5% 3.6% 
C81-C85: lymphoma (total)      388  2.9% 4.2% 16.1 1.32     472  3.0% 4.4% 21.4 1.67     860  2.9% 4.3% 
C88: malignant immunoproliferative disease        7  0.1% 0.1% 0.3 0.02      12  0.1% 0.1% 0.6 0.05      19  0.1% 0.1% 
C90: multiple myeloma      103  0.8% 1.1% 3.9 0.28     141  0.9% 1.3% 6.5 0.48     244  0.8% 1.2% 
C91: lymphoid leukaemia       98  0.7% 1.1% 4.1 0.32     171  1.1% 1.6% 7.8 0.60     269  0.9% 1.3% 
C92: myeloid leukaemia       79  0.6% 0.8% 3.2 0.25     103  0.7% 1.0% 4.7 0.34     182  0.6% 0.9% 
C93: monocytic leukaemia        1  <0.1% <0.1% 0.1 <0.01       1  <0.1% <0.1% 0.0 <0.01       2  <0.1% <0.1% 
C94: other specified leukaemia        1  <0.1% <0.1% 0.1 <0.01       6  <0.1% 0.1% 0.3 0.02       8  <0.1% <0.1% 
C95: unspecified leukaemia       13  0.1% 0.1% 0.4 0.02      16  0.1% 0.1% 0.7 0.03      28  0.1% 0.1% 
C91-C95: leukaemia (total)      192  1.4% 2.1% 7.9 0.60     297  1.9% 2.8% 13.5 0.98     489  1.7% 2.4% 
C96: other lymphoid and haematopoietic*      113  0.8% 1.2% 4.4 0.33     169  1.1% 1.6% 7.6 0.54     282  1.0% 1.4% 
D03: in situ: melanoma      278    11.7 0.99     239    11.0 0.93     518    
D04: in situ: carcinoma of skin     1,019    38.5 2.92     658    29.8 2.30    1,677    
D05: in situ: breast      340    15.8 1.28       1    0.0 <0.01     340    
D06: in situ: cervix     2,903    113.0 7.80         2,903    
D32-D33: benign: brain & CNS      117    4.9 0.40      49    2.2 0.19     166    
D42-D43: uncertain: brain & CNS       34    1.4 0.11      29    1.3 0.10      63    
 
*Incidence figures for C00-C96 and C96 presentedin this report include polycythaemia vera, myelodysplastic syndromes and chronic myeloproliferative disease, considered malignant in ICDO3 but previously classed as uncertain behaviour 
(and previously coded under ICD10 codes D45-D47).  
** D00-D48 tumours in this report exclude polycythaemia vera, myelodysplastic syndromes and chronic myeloproliferative disease (see note above).   
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13. APPENDIX II: SUMMARY TABLE-CANCER DEATHS: 2010-2012 
 
ICD10 cancer site (MORTALITY) FEMALES MALES TOTAL 
ASR†: age-standardised rate, cases per 100,000 
(standardised to the European population) 
annual  
average 
2010-2012 
% all 
cancers 
ASR† cumulative 
risk (%) to  
age 75y 
annual  
average 
2010-2012 
% all 
cancers 
ASR† cumulative 
risk (%) to  
age 75y 
annual  
average 
2010-2012 
% all 
cancer 
deaths 
C00-D48: All registered neoplasms   4,128  100.0% 154.7 10.49   4,634  100.0% 211.9 13.10         8,762  100.0% 
C00-C96: All invasive cancers   3,986  96.6% 150.0 10.30   4,480  96.7% 204.9 12.84         8,466  96.6% 
C00-C43, C45-C96: All invasive cancers, excluding NMSC   3,959  95.9% 149.2 10.27   4,428  95.6% 202.4 12.75         8,387  95.7% 
D00-D48: All non-invasive neoplasms     142  3.4% 4.7 0.22     154  3.3% 7.1 0.29           296  3.4% 
C00: lip       0   <0.1% 0.0 <0.01        1  <0.1% 0.1 <0.01              1  <0.1% 
C01: base of tongue       0   <0.1% 0.0 <0.01        3  0.1% 0.1 0.02              3  <0.1% 
C02: other tongue       12  0.3% 0.4 0.03       18  0.4% 0.9 0.08            31  0.4% 
C03: gum        2  <0.1% 0.1 0.01        2  <0.1% 0.1 0.01              4  <0.1% 
C04: floor of mouth        2  <0.1% 0.1 0.01        4  0.1% 0.2 0.03              6  0.1% 
C05: palate        2  <0.1% 0.1 0.01        2  <0.1% 0.1 0.01              4  <0.1% 
C06: other mouth        8  0.2% 0.3 0.02        7  0.1% 0.3 0.02            14  0.2% 
C07: parotid        3  0.1% 0.1 0.01        9  0.2% 0.4 0.01            12  0.1% 
C08: other salivary        3  0.1% 0.1 0.01        2  <0.1% 0.1 <0.01              5  0.1% 
C09: tonsil        3  0.1% 0.1 0.01       10  0.2% 0.5 0.04            13  0.1% 
C10: oropharynx        1  <0.1% 0.0 <0.01       12  0.3% 0.6 0.05            13  0.1% 
C11: nasopharynx        1  <0.1% 0.0 <0.01        9  0.2% 0.4 0.04            10  0.1% 
C12: pyriform        1  <0.1% 0.1 0.01        5  0.1% 0.2 0.02              7  0.1% 
C13: hypopharynx        2  0.1% 0.1 <0.01        3  0.1% 0.1 0.01              6  0.1% 
C14: other mouth/pharynx        4  0.1% 0.2 0.01       12  0.3% 0.5 0.07            16  0.2% 
C01-C14: mouth & pharynx       44  1.1% 1.7 0.13       99  2.1% 4.5 0.39           143  1.6% 
C15: oesophagus     120  2.9% 4.2 0.27     230  5.0% 10.6 0.81           350  4.0% 
C16: stomach     127  3.1% 4.5 0.27     199  4.3% 9.1 0.64           326  3.7% 
C17: small intestine        9  0.2% 0.3 0.01       11  0.2% 0.5 0.02            20  0.2% 
C18: colon     235  5.7% 8.1 0.51     283  6.1% 12.9 0.85           518  5.9% 
C19: rectosigmoid     112  2.7% 4.3 0.29     181  3.9% 8.3 0.63           293  3.3% 
C20: rectum       63  1.5% 2.3 0.14     107  2.3% 4.9 0.29           170  1.9% 
C21: anus        5  0.1% 0.2 0.01        6  0.1% 0.3 0.01            10  0.1% 
C18-C21: colorectal     416  10.1% 14.8 0.95     576  12.4% 26.3 1.78           992  11.3% 
C22: liver     111  2.7% 4.0 0.29     153  3.3% 7.1 0.52           265  3.0% 
C23: gallbladder       17  0.4% 0.6 0.04        6  0.1% 0.3 0.02            23  0.3% 
C24: other biliary        8  0.2% 0.3 0.02        7  0.1% 0.3 0.02            14  0.2% 
C25: pancreas     230  5.6% 8.4 0.55     258  5.6% 11.9 0.86           488  5.6% 
C26: other digestive       64  1.6% 2.2 0.14       71  1.5% 3.3 0.20           136  1.5% 
C30: nasal cavity/middle ear        1  <0.1% 0.0 <0.01        1  <0.1% 0.0 <0.01              2  <0.1% 
C31: sinuses        1  <0.1% 0.0 <0.01        3  0.1% 0.2 0.01              4  0.1% 
C32: larynx        6  0.2% 0.3 0.02       51  1.1% 2.4 0.18            58  0.7% 
C33: trachea        1  <0.1% 0.0 <0.01        1  <0.1% 0.0 <0.01              2  <0.1% 
C34: lung     743  18.0% 28.8 2.20   1,040  22.4% 47.4 3.57         1,783  20.4% 
C37: thymus        1  <0.1% 0.1 0.01        2  <0.1% 0.1 0.01              3  <0.1% 
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ICD10 cancer site (MORTALITY) FEMALES MALES TOTAL 
ASR†: age-standardised rate, cases per 100,000 
(standardised to the European population) 
annual  
average 
2010-2012 
% all 
cancers 
ASR† cumulative 
risk (%) to  
age 75y 
annual  
average 
2010-2012 
% all 
cancers 
ASR† cumulative 
risk (%) to  
age 75y 
annual  
average 
2010-2012 
% all 
cancer 
deaths 
C38: mediastinum        3  0.1% 0.1 0.01        1  <0.1% 0.1 0.01              4  <0.1% 
C39: other chest       0   <0.1% 0.0 <0.01        1  <0.1% 0.0 <0.01              1  <0.1% 
C40: bones, joints of limbs        1  <0.1% 0.0 <0.01        1  <0.1% 0.0 <0.01              2  <0.1% 
C41: bones, joints head and trunk        7  0.2% 0.3 0.02       10  0.2% 0.4 0.03            17  0.2% 
C43: melanoma skin       66  1.6% 2.5 0.18       87  1.9% 4.0 0.28           153  1.7% 
C44: non-melanoma skin (NMSC)       27  0.6% 0.8 0.03       52  1.1% 2.5 0.10            79  0.9% 
C45: mesothelioma        6  0.1% 0.2 0.02       30  0.7% 1.4 0.08            36  0.4% 
C46: Kaposi's sarcoma 0 <0.1% 0.0 <0.01        0  <0.1% 0.0 <0.01              0  <0.1% 
C47: peripheral nerves        1  <0.1% 0.1 <0.01        0  <0.1% 0.0 <0.01              1  <0.1% 
C48: peritoneum       11  0.3% 0.4 0.02        2  0.1% 0.1 0.01            13  0.1% 
C49: connective tissues       21  0.5% 0.9 0.08       25  0.5% 1.1 0.09            46  0.5% 
C50: breast     673  16.3% 26.4 2.04        9  0.2% 0.4 0.03           682  7.8% 
C51: vulva       18  0.4% 0.6 0.03                18  0.2% 
C52: vagina        5  0.1% 0.2 0.02                  5  0.1% 
C53: cervix       94  2.3% 4.0 0.33                94  1.1% 
C54: corpus uteri       81  2.0% 3.2 0.26                81  0.9% 
C55: uterus, NOS       24  0.6% 0.9 0.06                24  0.3% 
C56: ovary     279  6.8% 11.2 0.92               279  3.2% 
C57: other female genital        8  0.2% 0.3 0.03                  8  0.1% 
C58: placenta        0  <0.1% 0.0 <0.01                  0  <0.1% 
C60: penis            6  0.1% 0.3 0.02              6  0.1% 
C61: prostate         549  11.9% 25.3 1.04           549  6.3% 
C62: testis            5  0.1% 0.2 0.01              5  0.1% 
C63: other male genital            1  <0.1% 0.0 <0.01              1  <0.1% 
C64: kidney       57  1.4% 2.1 0.15     140  3.0% 6.4 0.45           197  2.2% 
C65: renal pelvis        1  <0.1% 0.0 <0.01        2  <0.1% 0.1 <0.01              2  <0.1% 
C66: ureter        3  0.1% 0.1 0.01        4  0.1% 0.2 0.01              7  0.1% 
C67: bladder       78  1.9% 2.6 0.14     128  2.8% 5.8 0.26           206  2.3% 
C68: other urinary        4  0.1% 0.1 <0.01        5  0.1% 0.2 0.02              9  0.1% 
C69: eye        3  0.1% 0.1 0.01        2  0.1% 0.1 0.01              5  0.1% 
C70: meninges        3  0.1% 0.1 0.01        0  <0.1% 0.0 <0.01              3  <0.1% 
C71: brain     102  2.5% 4.2 0.35     149  3.2% 6.7 0.56           250  2.9% 
C72: spinal cord        1  <0.1% 0.0 <0.01        0  <0.1% 0.0 <0.01              1  <0.1% 
C73: thyroid       15  0.4% 0.5 0.04       11  0.2% 0.5 0.05            26  0.3% 
C74: adrenal        5  0.1% 0.2 0.02        3  0.1% 0.1 0.01              8  0.1% 
C75: other endocrine        1  <0.1% 0.0 <0.01        3  0.1% 0.1 0.01              4  <0.1% 
C76: ill-defined site       11  0.3% 0.4 0.03       13  0.3% 0.6 0.03            25  0.3% 
C80: unknown primary site     164  4.0% 5.8 0.40     129  2.8% 5.8 0.40           293  3.3% 
C81: Hodgkin disease       11  0.3% 0.4 0.02       10  0.2% 0.4 0.03            21  0.2% 
C82: follicular non-Hodgkin lymphoma        5  0.1% 0.2 0.01        7  0.2% 0.3 0.02            12  0.1% 
C83: diffuse non-Hodgkin lymphoma       11  0.3% 0.4 0.03       17  0.4% 0.8 0.04            29  0.3% 
C84: peripheral and cutaneous T cell lymphoma        7  0.2% 0.3 0.01       12  0.3% 0.6 0.04            20  0.2% 
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ICD10 cancer site (MORTALITY) FEMALES MALES TOTAL 
ASR†: age-standardised rate, cases per 100,000 
(standardised to the European population) 
annual  
average 
2010-2012 
% all 
cancers 
ASR† cumulative 
risk (%) to  
age 75y 
annual  
average 
2010-2012 
% all 
cancers 
ASR† cumulative 
risk (%) to  
age 75y 
annual  
average 
2010-2012 
% all 
cancer 
deaths 
C85: other and unspecified NHL       93  2.3% 3.3 0.25     104  2.3% 4.7 0.28           198  2.3% 
C82-C85: all non-Hodgkin lymphoma     117  2.8% 4.3 0.30     141  3.1% 6.4 0.38           258  2.9% 
C81-C85: lymphoma (total)     128  3.1% 4.7 0.32     151  3.3% 6.9 0.42           280  3.2% 
C88: malignant immunoproliferative disease        1  <0.1% 0.0 <0.01        3  0.1% 0.1 0.01              4  <0.1% 
C90: multiple myeloma       76  1.8% 2.6 0.16       79  1.7% 3.6 0.24           155  1.8% 
C91: lymphoid leukaemia       29  0.7% 0.9 0.03       49  1.1% 2.3 0.14            79  0.9% 
C92: myeloid leukaemia       51  1.2% 1.9 0.13       78  1.7% 3.6 0.22           129  1.5% 
C93: monocytic leukaemia        0  <0.1% 0.0 <0.01        0  <0.1% 0.0 <0.01              1  <0.1% 
C94: other specified leukaemia        0  <0.1% 0.0 <0.01        1  <0.1% 0.0 <0.01              1  <0.1% 
C95: unspecified leukaemia        6  0.1% 0.2 0.01        6  0.1% 0.3 0.02            12  0.1% 
C91-C95: leukaemia (total)       86  2.1% 3.0 0.17     133  2.9% 6.0 0.38           219  2.5% 
C96: other lymphoid and haematopoietic        1  <0.1% 0.0 <0.01        0  <0.1% 0.0 <0.01              1  <0.1% 
D03: in situ: melanoma        0  <0.1% 0.0 <0.01        0  <0.1% 0.0 <0.01              0  <0.1% 
D04: in situ: carcinoma of skin        0  <0.1% 0.0 <0.01  <0.1%                0  <0.1% 
D32-D33: benign: brain & CNS        8  0.2% 0.2 0.01        4  0.1% 0.2 <0.01            12  0.1% 
D42-D43: uncertain: brain & CNS       10  0.2% 0.3 0.03       13  0.3% 0.6 0.04            23  0.3% 
 
 
